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ABSTRACT 
 
Mastitis is a syndrome manifested by mammary gland inflammation which is thought to cause 
between $300 and $400 million in annual losses to the Canadian Dairy Industry.  Studies have 
indicated that S. aureus may cause the production of anti-inflammatory cytokines which may 
enhance its survival within the bovine mammary gland.  However, other studies have reported 
differing results following S. aureus intramammary infection (IMI).  This thesis tested the 
hypothesis that S. aureus generated anti-inflammatory cytokine responses at the site of infection.  
In the first objective, different S. aureus isolates were screened for their effects on cytokine 
production (IFN-γ, TNF-α, IL-4 and IL-10) by bovine peripheral blood mononuclear cells 
(PBMCs) in vitro.  Nine S. aureus isolates were co-cultured with PBMCs from lactating dairy 
cattle.  Cattle used in the study had recall immune responses to S. aureus.  The majority (6/9) of 
S. aureus isolates had minor effectors on cytokine production.  The three remaining isolates 
generated large cytokine responses with both pro-inflammatory (IFN-γ and TNF-α) and anti-
inflammatory (IL-4 and IL-10) characteristics.  Two of these three isolates were tested in vivo by 
experimentally infecting lactating ewes.  Cytokine production was characterized in the teat end, 
the mammary parenchyma and the supramammary lymph nodes (SMLNs).  One isolate 
generated anti-inflammatory responses in vivo (IL-4 and IL-10) whilst the other generated both 
pro-inflammatory (IFN-γ) and anti-inflammatory (IL-10) responses in vivo.  Given that some 
studies have suggested a role of staphylococcal enterotoxin C (sec) in the generation of anti-
inflammatory responses, the role of sec was also investigated using bovine PBMCs.  When 
purified SEC protein was co-cultured with PBMCs from beef steers, anti-inflammatory cytokines 
were produced.  However, a S. aureus strain which was transformed for the sec gene did not 
affect cytokine production when co-cultured with PBMCs from lactating dairy cattle.  The results 
of this thesis suggest that S. aureus infection can cause anti-inflammatory cytokine production 
but the response depends on the isolate causing the infection.  Furthermore, the role of sec 
appears to be minimal. 
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1.  INTRODUCTION 
Staphylococcus aureus is one of the most common mastitis pathogens in Canadian Dairy Cattle.  
Mastitis as a disease syndrome manifests as inflammation of the mammary gland which causes 
annual losses of $300 - $400 million to Canadian dairies [1].  A survey of bulk tank milk in 
Prince Edward Island reported that S. aureus was present in 74% of the bulk tanks sampled [2].  
A cohort study of 84 cows in Prince Edward Island reported that up to 5.8% of cows had a 
detectable S. aureus intramammary infection (IMI) during lactation [3].  Currently, no vaccine is 
available which reliably prevents S. aureus IMI.  Traditional control measures such as dairy cow 
hygiene, management and antimicrobial treatment do not always reliably prevent IMI with S. 
aureus. 
 
One potential reason for the ineffectiveness of current vaccines is that S. aureus IMI induces 
poor immune responses in the bovine mammary gland.  Immune responses can be classified 
according to whether they promote a pro-inflammatory environment or an anti-inflammatory 
environment.  Pro-inflammatory responses are characterized by the presence of the cytokines 
IFN-γ and IL-12.  Anti-inflammatory responses are characterized by the presence of the 
cytokines IL-4, IL-10 and TGF-β.  Studies have suggested that S. aureus induces ineffective 
immune responses in the mammary gland [4-6].  Specifically, S. aureus has been reported to 
induce anti-inflammatory responses in the gland.  Given that S. aureus may become intracellular, 
a pro-inflammatory response would be appropriate to clear S. aureus intramammary infection.  
Other evidence suggests that the anti-inflammatory responses may be mediated by SEC [7, 8].  
However, many studies report differing effects of S. aureus on mammary cellular immunity.  A 
potential explanation for these observations is that studies use different S. aureus which have 
differing effects on cellular immunity.   Furthermore, the majority of studies have evaluated 
cellular immune responses to S. aureus in cells from blood and mammary secretions.  Due to the 
major differences between blood and milk, and the fact that immune effectors in milk are rapidly 
removed from the mammary gland during the milking process, studies of the site of infection 
should provide more relevant information about the effect of S. aureus on mammary cellular 
immunity.  Finally, no studies have focused on the role of dendritic cells in S. aureus 
intramammary infection.  Dendritic cells are of interest as they play a major role in directing 
immune responses hence may be a major target of S. aureus during IMI. 
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2.  HYPOTHESIS AND OBJECTIVES 
The hypothesis to be tested is that S. aureus IMI induced by wild type isolates from dairy cattle 
results in the induction of anti-inflammatory responses in the supramammary lymph nodes 
(SMLNs), mammary parenchyma and mammary teat ends of ewes.   
 
1. Screen bovine mammary S. aureus isolates and determine whether they alter cytokine 
production by bovine peripheral blood mononuclear cells (PBMCs) in vitro.  The strains 
that alter cytokine production will be selected for use in the subsequent objectives. 
2. Establish a model of ovine intramammary infection with S. aureus. 
3. Characterize T lymphocyte populations, DC populations and cytokine production in the 
supramammary lymph nodes, mammary parenchymal tissue and teat ends of ewes 
following intramammary infection with the selected S. aureus strains. 
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3.  LITERATURE REVIEW 
 
3.1 Bovine Staphylococcus aureus mastitis 
Mastitis is a syndrome manifest by inflammation of the mammary gland.  As a syndrome, 
mastitis is thought to cause $300-$400 million annual losses to the Canadian dairy industry [1].  
The major causes of mastitis in dairy cattle are bacterial [9].  Bacterial mastitis pathogens are 
divided according to their reservoir of infection and manner of transmission.  Contagious mastitis 
pathogens have a reservoir within the mammary gland and are transmitted at the time of milking.  
Examples of contagious pathogens include Staphylococcus aureus, Streptococcus agalactiae, 
Corynebacterium bovis, Mycoplasma spp. and S. dysgalactiae [10].  Environmental mastitis 
pathogens have reservoir in the environment of the cow and are transmitted between milkings.  
Examples of environmental pathogens include Escherichia coli and S. uberis [11]. 
 
Staphylococcus aureus is considered to be the most common contagious mastitis pathogen [2].  It 
is a Gram positive, spore-forming, facultative anaerobic coccus [12].  A survey of bulk tank milk 
in Prince Edward Island reported that S. aureus was present in 74% of the bulk tanks sampled 
[2].  A cohort study of 84 cows in Prince Edward Island reported that up to 5.8% of cows had a 
detectable S. aureus intramammary infection (IMI) during lactation [3].  Staphylococcus aureus 
IMI usually results in subclinical mastitis causing decreased milk production and increased milk 
somatic cell count (SCC) [13-15].  Milk with low SCC has increased shelf life and greater cheese 
yield per unit weight therefore a premium is paid for low SCC milk [16, 17].   
 
Given that S. aureus has a major detrimental effect on the dairy industry, several treatment and 
control strategies have been developed.  This chapter will discuss these strategies and their 
efficacy.  The host responses to S. aureus and the strategies by which S. aureus evades these host 
responses will also be discussed and the need for a better understanding of host responses to S. 
aureus will be explained. 
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3.2 Treatment of bovine Staphylococcus aureus mastitis 
3.2.1 Antimicrobial therapy 
As S. aureus mastitis is a bacterial infection, antimicrobials have been central to treatment 
strategies.  Antimicrobial agents are administered either during lactation or at the beginning of 
the dry period.  The route of administration can be either parenteral or intramammary.  Cure rates 
of S. aureus mastitis are highly variable. For example, cure rates as low as 9.1% [18] and as high 
as 100% [19] have been reported. 
 
Several host, pathogen and treatment factors have been associated with cure rates during 
lactation [20, 21].  The major risk factors were all host factors including a lactation number 
greater than two, SCC greater than 10
6
 cells/ml, infection in the hind quarters and stage of 
lactation greater than 200 days.  Antimicrobial resistance is a pathogen factor which may 
decrease the cure rate of S. aureus mastitis during lactation.  A study which assessed parenteral 
and local treatment of S. aureus IMI with procaine penicillin G or clavulanic acid potentiated 
amoxicillin reported that cure rates of penicillin-resistant S. aureus strains were significantly 
lower than those of penicillin-susceptible strains regardless of route of administration or 
antimicrobial used [22]. 
 
Dry cow therapy is considered to be a major part of mastitis control programs [23].  Sol and 
coworkers studied the association of host factors with bacteriologic cure of S. aureus following 
dry cow treatment [24].  The major risk factors were high SCC, increased age of cattle and 
infections in multiple quarters.  Generally cure rates for antimicrobial therapy at dry off range 
from 50-80% [25].  Cows harbouring S. aureus that remain in the herd during the dry period 
represent a reservoir for infection during the next lactation. 
 
Whilst all these factors are important in predicting whether antimicrobial treatment may be 
effective, it is important to consider that antimicrobial treatment is a major part of the “gold 
standard” mastitis control program [23].  However, the evidence discussed shows that 
antimicrobial treatment does not completely cure S. aureus mastitis. This may be due to the 
increasing risk of S. aureus mastitis with parity and stage of lactation [26].  Animals that are 
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more likely to possess chronic infections are less likely to be cured and act as a reservoir in the 
herd.  This realization has led a search for alternative treatments. 
 
3.2.2 Other proposed treatments 
The use of antimicrobial therapy in combination with vaccines is a relatively recent 
development.  A small study showed no enhancement of S. aureus cure rates when a S. aureus 
bacterin was used alongside extended pirlimycin therapy compared with extended pirlimycin 
therapy alone [27].  A larger study showed significantly increased cure rates in animals treated 
with the same S. aureus bacterin alongside extended pirlimycin therapy [28].  Unfortunately, this 
study used untreated animals as a control group rather than pirlimycin treated animals therefore 
the effect of the bacterin cannot be assessed.  Larger scale, better designed studies are required 
before conclusions can be drawn. 
 
Bacteriophages have been the subject of investigation as an alternative treatment to many 
bacterial diseases [29].  Bacteriophages isolated from farmyard slurry [30] and from sewage 
entering a water treatment plant [31] are able to lyse S. aureus in vitro.  Lytic activity has been 
attributed to the endolysin gene [32].  Administration of bacteriophages to healthy animals has 
varying effects with one study reporting no increase in SCC following administration [30] and a 
different study reporting large increases in SCC following administration [33].  Bacteriophages 
have not been demonstrated to clear S. aureus mastitis.  Administration of 10
11
 pfu bacteriophage 
K from S. aureus strain ATCC 19685 did not result in a significant increase in S. aureus mastitis 
cure rates when compared with saline treatment [33].  A further study reported that 
bacteriophage K was unable to replicate in raw milk [34].  Adsorption of milk whey proteins to 
the surface of S. aureus inhibits lytic infection with bacteriophage K [29].  If bacteriophage 
therapy is to be of use in the treatment of bovine mastitis, these problems will have to be 
overcome whilst ensuring that the treatment is affordable to the producer. 
 
Bacteriocins are short peptide antimicrobials which are produced by bacteria [35].  Early studies 
reported that nisin can inhibit S. aureus growth in vitro [35] and reduce S. aureus concentrations 
on teat ends [36].  Treatment of subclinical mastitis with nisin, a product of Lactococcus lactis 
[37], resulted in a 50% cure rate which was significantly greater than untreated controls [38].  
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This study did not compare nisin with conventional antimicrobials.  Lacticin 3147, which is also 
produced by Lactococcus lactis, was incorporated into a bismuth-based teat seal and reduced 
shedding of S. aureus both before and after S. aureus challenge [39].  Whilst this therapy shows 
promise, cure rates were not determined therefore a comparison of the effects of lacticin with 
conventional therapies cannot be made.  Further studies should focus on cure rates and 
comparisons with conventional antimicrobial therapy. 
 
Lactoferrin is an iron binding protein primarily occurring in neutrophil granules [40].  It appears 
to have a variable effect on S. aureus in either milk whey or culture broth [40, 41].  These results 
may be strain-dependent [40].  Due to the variable effect of lactoferrin when used in isolation, 
studies have evaluated the ability of lactoferrin to enhance cure rates of antimicrobial therapy.  A 
combination of lactoferrin and penicillin G significantly increased chronic S. aureus mastitis 
cure rates 15 days after intramammary infusion of S. aureus in late lactation cows when 
compared with no treatment, lactoferrin alone or penicillin G alone.  Cure rates for all treated 
groups were not significantly higher in animals that were infected in late lactation then treated 
following parturition [42].  Further studies on naturally occurring S. aureus infections need to be 
performed before lactoferrin can be recommended as a treatment option. 
 
Whilst cows transgenic for antimicrobial agents have been developed [43], this is a preventive 
rather than treatment strategy therefore will not be considered here.  Attempts have been made to 
transfer the lysostaphin gene into the mammary gland.  Lysostaphin is a protein that is effective 
at lysing S. aureus and can be transferred into the goat mammary gland by a human adenoviral 
vector [44].  Unfortunately, a strong immune response occurred to both the adenovirus and 
lysostaphin [44].  Use of eukaryotic expression vectors may overcome this problem [45].  This 
method allowed for the expression of the antimicrobial peptides bovine lactoferricin and bovine 
tracheal antimicrobial peptide in goats for up to 6 days following intramammary infusion with a 
vector encoding these peptides [45].  Genomic therapies appear promising but efficacy has not 
been determined in bovine mammary glands and the potential cost to the producer may be 
prohibitive and may lead to the selection of resistant S. aureus strains. 
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Cytokines have been studied as a potential therapy for S. aureus mastitis due to the ability of IL-
1β pretreatment to enhance killing of S. aureus by neutrophils in vitro [46] and the ability of 
TNF-α pretreatment to enhance killing of S. aureus in the mouse mammary gland [47].  Use of 
recombinant bovine IL-2 or IL-1β resulted in cure rates for chronic S. aureus mastitis in early to 
mid-lactation cattle of 52% and 75% respectively [48].  Recombinant bovine IL-2 has also been 
studied as an adjunct to conventional antimicrobial therapy.  Cure rates following administration 
of IL-2, cephapirin, and IL-2 combined with cephapirin were 31%, 42% and 85%, respectively in 
early to mid-lactation cattle [49].  Combination therapy with IL-2 and cephapirin significantly 
increased cure rates compared with IL-2 therapy alone.  A further study demonstrated 
significantly decreased bacterial shedding from mammary glands following addition of IL-2 to 
cephapirin although cure rates were not reported [50]. 
 
Egg yolk immunoglobulin (IgY) specific for bovine S. aureus has been reported to enhance 
phagocytosis of S. aureus by macrophages [51].  A comparison of IgY and penicillin in the 
treatment of clinical or experimental S. aureus mastitis showed that IgY performed significantly 
better than penicillin with cure rates for clinical and experimental mastitis being 50% and 83.3%, 
respectively [52].  This therapy needs to be tested in subclinical, chronic mastitis.  A 50% cure 
rate of clinical mastitis remains insufficient to eliminate S. aureus IMI from the herd. 
 
 
3.3 Control of bovine Staphylococcus aureus mastitis 
3.3.1 Management-based control measures 
Management-based control measures include milking hygiene, post-milking teat disinfection, 
culling of chronically infected cattle and appropriate use of antibiotic therapy.  The use of 
antibiotic therapy has already been discussed, therefore milking hygiene and culling of 
chronically infected cattle will be focused on here. 
 
Neave and co-workers [53] studied hygiene programs for mastitis control in 15 dairy herds. Two 
levels of hygiene were studied, full and partial.  Full hygiene consisted of single use udder towels 
for cleaning the udder before milking, wearing of rubber gloves by milkers, sterilization of teat 
cups before milking each cow and post-milking teat disinfection.  Partial hygiene consisted of all 
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the above measures with the exception of teat cup pasteurization.  Full hygiene reduced the 
incidence of new S. aureus IMI over an 18-month period by 62% and partial hygiene reduced the 
incidence of new S. aureus IMI by 55% when both were compared with no hygiene at the time 
of milking.  Additional control procedures were studied in a herd practicing full hygiene that had 
suffered an outbreak of S. aureus mastitis [54, 55].  These included segregation of cattle with S. 
aureus IMI, intensified culling of animals harboring S. aureus IMI, and permanently ceasing 
lactation in S. aureus infected quarters of cattle with S. aureus IMI in a single mammary quarter.  
These practices in combination with full hygiene reduced the incidence of S. aureus IMI from 
3.4 cases/100 cow months to 0.35 cases/100 cow months and reduced S. aureus IMI prevalence 
from 22% to 8%.  A similar study in nine Italian dairy herds [56] which instituted single-use 
cloth towels to prepare teats before milking, practiced forestripping before milking unit 
attachment, used a post-milking germicidal teat disinfectant, segregated S. aureus infected cattle 
from the rest of the herd, milked these cattle last, and used blanket dry cow antibiotic therapy.  
Using these practices, there was a reduction in the incidence of S. aureus IMI from as many as 
40 cases/100 cow-months to ≤ 1 case/100 cow-months. 
 
Given that the reservoir of S. aureus IMI is the mammary gland of infected cattle, addition of 
infected cattle into a herd would clearly increase the risk of S. aureus IMI in a dairy herd.  
Screening of replacement animals has been proposed [57]. 
 
From this evidence, it appears that a significant degree of control of S. aureus mastitis can be 
achieved at a management level.  However, given the continued prevalence of the disease in the 
dairy industry, additional control measures are required.  Given that vaccination has been used to 
control many veterinary infectious diseases, many attempts have been made to vaccinate cattle 
against S. aureus IMI. 
 
3.3.2 Vaccination 
Attempts to vaccinate against S. aureus are summarized in table 3.1.  The earliest commercial 
attempt at vaccination was made in 1966 [58].  The vaccine contained whole cell lysates of five 
S. aureus strains in an aluminum hydroxide adjuvant.  The vaccine was studied in cows with 
naturally-occurring S. aureus IMI in three dairy herds over a six-month period.  Following  
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Table 3.1.  Summary of previous S. aureus vaccine studies 
 
  
Reference [58] [59] [60] [61] [62] [64] 
Year 1966 1975 1985 2006 1975 1980 
Vaccine type Bacterin Bacterin Bacterin Bacterin Bacterin Bacterin 
Trial type Field Chall. Chall. Chall. Chall. Chall. 
Serum antibody ↑IgG N/E N/E N/E NC NC 
Milk antibody ↑IgG N/E N/E N/E NC ↑IgA/M/G2 
Effect on new IMI ↓ ↓ NC NC ↓ NC 
 
Reference  [66] [67] [68] [69] [71] [74]  
Year  1984 2003 1994 2005 1997 2004  
Vaccine type  Live Protein A CP5 CP5/8/336 CP5/α-toxin FnBP  
Trial type  Chall. N/A N/A N/A N/A Chall.  
Serum antibody  ↑IgG1/2 ↑IgG ↑IgG2 ↑IgG1/2 ↑IgG N/E  
Milk antibody  N/E N/E N/E N/E ↑IgG N/E  
Effect on new IMI  ↓ N/A N/A N/A N/A ↓  
 
Reference [75] [76] [77] [78] [84] 
Year Published 1992 1993 1996 1994 2006 
Vaccine type Bacterin Bacterin Bacterin Bacterin GapC/B 
Trial type Chall. Chall. Field Field N/A 
Serum antibody ↑IgG2 ↑IgG1/2 N/E N/E ↑IgG 
Milk antibody ↑IgG2 N/E N/E ↑IgG2 ↑IgG 
Effect on IMI NC ↓ ↓ ↓ N/A 
 
Reference  [85] [87] [88] [90] [91] 
Year Published  2008 1997 1997 2003 2003 
Vaccine type  SEC Bacterin Bacterin Bacterin Bacterin 
Trial type  Chall. Field Field Chall. Field 
Serum antibody  N/E N/E N/E ↑IgG N/E 
Milk antibody  N/E N/E N/E ↑IgG N/E 
Effect on IMI  ↓ ↓ ↓ ↓ NC 
 
Chall. Denotes challenge trial 
N/A denotes not applicable 
N/E denotes not evaluated 
NC denoted unchanged 
10 
 
vaccination, significantly fewer vaccinates than controls developed a S. aureus IMI.  Vaccinates 
also had increased serum and milk whey total immunoglobulin titers against staphylococci thirty 
days after the second vaccination.  This vaccine is currently marketed as Lysigin (Boehringer 
Ingelheim Vetmedica Inc., St. Joseph, MO, USA).  Lysigin was also tested using an 
experimental intramammary challenge model [59].  Vaccinated cattle showed a reduced 
incidence of S. aureus IMI, reduced clinical signs and reduced SCC after challenge. However, 
the challenge model used in this study was inconsistent between cattle, making analysis of the 
results problematic.  Pankey and co-workers [60] also tested Lysigin using an experimental 
challenge model.  Cattle were challenged by immersing teat ends in a suspension of S. aureus 
(ATCC 29740) immediately after milking five days per week for six months during lactation.  
These procedures were repeated in the same animals for six-month periods during three 
consecutive lactations.  The incidence of S. aureus infected mammary quarters immediately after 
challenge did not vary between groups although vaccinates had a significantly decreased 
incidence of chronically infected quarters, increased spontaneous quarter cure rate and decreased 
SCC when compared with non-vaccinated controls.  The spontaneous cure rate for animals 
vaccinated with Lysigin was 73% compared with 47% for control animals.  The efficacy of 
different vaccine formulations (2 experimental formulations and commercially available Lysigin) 
in the prevention of S. aureus IMI in dairy heifers was evaluated using an intramammary 
challenge model [61].  Cattle vaccinated with commercially available Lysigin had a significantly 
lower mean duration of clinical mastitis and lower total mastitis score post-challenge than 
controls.  There was no evidence of a difference between any vaccinated group and controls with 
regard to S. aureus clearance rates post-challenge. 
 
Given the inability of Lysigin to consistently protect against S. aureus IMI, several other 
vaccination strategies have been attempted.  Vaccination with a killed vaccine made up of one of 
three S. aureus strains (Mexi, BB and 3528) did not increase IgG1, IgG2, IgM or IgA titers in 
serum or milk [62]. Cattle vaccinated with strain 3528 were resistant to infection with the low-
virulence (based on clinical severity of disease) strain Mexi but were not resistant to the high 
virulence strain BB. The authors concluded that vaccination was unlikely to prevent infection of 
the bovine mammary gland by S. aureus.  A different heat-killed S. aureus bacterin containing 
Freund’s incomplete adjuvant did not alter bacterial growth rates in milk from vaccinates when 
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compared with controls [63].  Guidry and co-workers [64] attempted local immunization with 
heat-killed S. aureus in four late lactation dairy cows. The vaccine was administered to two 
quarters of each cow.  One immunized and one control quarter per cow was challenged with S. 
aureus. All but one challenge quarter became infected although significant increases in IgA, IgM 
and IgG2 were detected in immunized quarters when compared with control quarters.  These 
immunoglobulins were able to opsonize S. aureus for phagocytosis by neutrophils.  
 
Live vaccines have been used as another strategy to immunize cattle against S. aureus IMI.  A 
live attenuated vaccine should stimulate cell-mediated immunity as well as humoral immunity. 
Due to the ability of S. aureus to become intracellular [65], a vaccine that stimulates cell 
mediated immunity may have increased efficacy in clearing S. aureus IMI.  Watson [66] tested a 
live attenuated S. aureus vaccine using dairy heifers in an experimental challenge model.  
Animals were vaccinated subcutaneously at eight and five weeks prepartum. Vaccinates had 
increased IgG1 and IgG2 titers in serum following the first vaccination and immediately prior to 
challenge.   No vaccinates shed S. aureus in the milk postchallenge whereas two control animals 
shed S. aureus in the milk 24 hours postchallenge.  One of the control heifers remained infected 
for the duration of the study.  Milk production in controls decreased after challenge whereas milk 
production in vaccinates remained unchanged.  Although this vaccine appears promising, the 
study was carried out in only 7 animals so few conclusions can be drawn. 
 
Several studies have focused on immunization against S. aureus virulence factors.  Vaccination 
using protein A has been studied [67].  Three groups of five animals were studied: 1) 
unvaccinated controls, 2) immunization with plasmids containing green fluorescent protein 
(GFP) and protein A and a saline adjuvant, and 3) immunization with plasmids containing GFP 
and protein A in an aluminum phosphate adjuvant. Cattle vaccinated with either vaccine had 
significantly higher serum IgG levels against protein A than unvaccinated controls.  There was 
no significant difference between the two vaccinated groups and controls. Six of the 15 animals 
(3 vaccinates and 3 controls) received a booster of protein A five months into lactation. Both 
vaccinates and controls had a serum IgG response to the booster and the difference between 
groups was not significant. Neither the effect of the vaccine on mammary immunity nor the 
ability of the vaccine to prevent S. aureus IMI was studied. 
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Vaccination with either purified S. aureus capsular polysaccharide 5 (CP5) or purified CP5 
conjugated to ovalbumin in Freund’s incomplete adjuvant has been attempted [68].  Purified CP5 
alone did not elicit an antibody response in serum. Vaccination with a CP5-ovalbumin conjugate 
elicited an IgG2 response that lasted for 4 weeks after vaccination. Cattle vaccinated with the 
CP5-ovalbumin conjugate received a booster of the conjugate 3 months after first vaccination 
that resulted in an IgG2 response in serum of greater magnitude than after the first vaccination. 
Milk antibody responses and the ability of the vaccine to prevent S. aureus IMI were not studied. 
A recent study into CP used a trivalent vaccine consisting of three S. aureus strains expressing 
either CPs 5, 8 or 336 [69].  A survey of S. aureus isolates from bovine mastitis cases reported 
that 100% of isolates from the USA and 98% of isolates from Europe expressed either CP5, 8 or 
336 [70].  Several formulations were studied: 1) trivalent vaccine alone, 2) trivalent vaccine 
precipitated in Freund’s incomplete adjuvant, 3) trivalent vaccine emulsified in aluminum 
hydroxide or 4) Freund’s incomplete adjuvant alone. When compared with Freund’s incomplete 
adjuvant alone, animals from the other groups had increased serum IgG1 and IgG2 against CPs 5, 
8 and 336 following vaccination. Furthermore, vaccinated cattle had increased percentages of 
total CD4+ and CD8+ lymphocytes in peripheral blood following vaccination when compared 
with animals administered Freund’s incomplete adjuvant alone.  Unfortunately, the ability of this 
vaccine to prevent S. aureus IMI was not tested. 
 
A different approach was to use staphylococcal α-toxin in conjunction with CP5 [71].  Three 
vaccines were evaluated in 10 cows: 1) unconjugated α-toxin with Freund’s incomplete adjuvant 
(n = 2), 2) unconjugated α-toxin and unconjugated CP5 with Freund’s incomplete adjuvant (n = 
2) or 3) CP5-alpha toxin conjugate with Freund’s incomplete adjuvant (n = 2). Controls received 
Freund’s incomplete adjuvant alone (n = 4). All vaccinated cattle had increased serum and milk 
anti-α-toxin antibody titers in response to vaccination.  No inflammatory cell recruitment into the 
mammary gland occurred in cows vaccinated with the CP5-alpha toxin conjugate after 
experimental intramammary challenge with α-toxin.  A different study [72] immunized cattle 
with S. aureus α-toxin alone. When challenged with α-toxin, immunized cattle exhibited an early 
and large-scale recruitment of neutrophils as well as CD8+ and CD4+ lymphocytes into the 
mammary gland.  However, no data was presented regarding protection against S. aureus IMI in 
this study. 
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Attempts have been made to vaccinate cattle against fibronectin-binding protein (FnBP).  Mamo 
and co-workers [73] evaluated four vaccines: 1) FnBP conjugated to two IgG binding domains of 
protein A (ZZ-FnBP), 2) FnBP conjugated to β-galactosidase (Gal-FnBP), 3) FnBP conjugated 
to 2 albumin binding domains of protein G (BB-FnBP) and 4) ZZ-FnBP-α-toxin conjugate. The 
vaccines were evaluated in a murine experimental intramammary challenge model. All 
vaccinated mice had significantly reduced severity of clinical mastitis after challenge when 
compared with unvaccinated controls. Animals vaccinated with ZZ-FnBP had significantly 
reduced shedding of S. aureus from infected glands after challenge. All vaccinates also had 
increased IgG levels against FnBP after challenge but the data were not statistically analyzed.  
Shkreta and coworkers [74] tested a DNA vaccine encoding FnBP and clumping factor A (ClfA), 
a putative S. aureus virulence factor.  Four heifers in their seventh month of gestation were 
vaccinated twice with the DNA vaccine followed by a booster with recombinant FnBP and ClfA.  
Four heifers served as unvaccinated controls. Three weeks after calving, three mammary quarters 
of each study animal were challenged with 900 cfu of S. aureus (Newbould 305 strain). 
Vaccinates showed decreased serum haptoglobin levels (an acute phase protein), heart rate and 
body temperature between 24 and 72 hours after challenge when compared with control. Also, 
vaccinates had significantly fewer S. aureus infected mammary quarters 21 days after challenge. 
A bacterin containing killed S. aureus cultured under conditions promoting formation of a 
pseudocapsule was combined with a staphylococcal toxoid and a mineral oil and dextran 
adjuvant.  The vaccine was tested in Friesian and Australian Illawarra Shorthorn heifers [75].  
The dextran adjuvant was included to induce an IgG2 response.  Infection rates after 
experimental intramammary challenge were not significantly different between vaccinates and 
controls for all experiments. However, if the vaccine was administered at 21 and 35 days 
postpartum, vaccinates had significantly increased milk production during the 25 days after 
challenge compared with controls. Also, if the vaccine was administered once two months before 
calving with a booster dose three months later, vaccinates showed significantly increased serum 
and milk IgG2 against S. aureus following the booster vaccination and before challenge. 
Vaccinates immunized once two months before calving with a booster dose three months later 
also had significantly increased milk production during the 21 days after challenge when 
compared with controls.  Nickerson and co-workers [76] evaluated this vaccine in primiparous 
Jersey heifers (n = 12). Vaccinates received the vaccine either intramuscularly (n = 4) or in the 
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region of the SMLN (n = 4). Vaccinates had significantly increased IgG, IgG1 and IgG2 against 
S. aureus in serum following vaccination compared with controls. However, titers were not 
presented for cattle that were vaccinated in either site. Following experimental intramammary 
challenge with S. aureus, 11/12 challenged quarters in control cows, 4/11 challenged quarters in 
cows vaccinated intramuscularly and 6/10 challenged quarters in cows vaccinated in the region 
of the SMLN became infected with S. aureus. Finally, Watson and coworkers [77] evaluated this 
vaccine in seven commercial dairy herds in Australia.  Cattle were vaccinated at the beginning of 
the third trimester of pregnancy (heifers) and at dry off (lactating cows). The only significant 
difference was in the herd with the highest prevalence of clinical S. aureus mastitis (37.7%). In 
this herd, the cumulative prevalence of S. aureus IMI during the seven months after vaccination 
was significantly lower for vaccinates. 
 
Nordhaug and co-workers [78, 79] developed a bacterin consisting of whole killed S. aureus with 
pseudocapsule and α and β toxoids in a mineral oil adjuvant. In a field study, Holstein cattle were 
vaccinated (n = 58) at 8 and 2 weeks prior to calving and compared with unvaccinated controls 
(n = 50). The relative risk of S. aureus IMI in the subsequent lactation was significantly lower 
for vaccinates than controls and vaccinated cattle had an 8.6% prevalence of S. aureus IMI 
during the subsequent lactation compared with 16.0% for controls. Vaccinates had significantly 
higher IgG2 in milk against pseudocapsule during the 120 days after second vaccination. Anti-α-
toxin IgG in milk was significantly higher for vaccinates than controls throughout lactation.  
Anti-β-toxin IgG in milk was only significantly higher for vaccinates compared with controls 
during late lactation. 
 
Attempts have been made to vaccinate cattle against the GapC and GapB surface proteins of S. 
aureus.  These proteins have a conserved structure among multiple bovine mammary S. aureus 
isolates [80].  Studies of streptococcal mastitis have revealed that immunization with 
recombinant GapC from Streptococcus uberis decreased the severity of streptococcal mastitis 
following experimental S. uberis challenge [81].  Similar results were observed when animals 
were immunized with recombinant GapC from Streptococcus dysgalactiae and challenged with 
S. dysgalactiae [82].  Vaccination of mice with a GapC/B chimera resulted in strong humoral 
and cell mediated immune responses in blood [83].  An attempt was made to immunize cattle 
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with a DNA vaccine encoding the bovine GapC/B chimera or with purified recombinant GapC/B 
protein with or without a boost with recombinant protein [84].  The DNA vaccines alone were 
unable to generate significant humoral or cell mediated immune responses against the 
recombinant antigens but significant responses were observed in animals either immunized with 
recombinant protein or immunized with DNA and boosted with recombinant proteins. 
 
An attempt has been made to immunize cattle against S. aureus by immunizing against SEC.  
Cattle were vaccinated with a S. aureus bacterin containing a SEC mutant protein and then 
subjected to experimental intramammary challenge with a SEC secreting S. aureus strain.  
Vaccinated cattle did not develop S. aureus IMI whereas 75% of unvaccinated controls 
developed S. aureus IMI [85].  Given that 10% of bovine mammary S. aureus isolates express 
SEC [86], this vaccine may not provide broad-based protection against S. aureus. 
 
A multivalent mastitis vaccine has been evaluated in heifers in Argentina [87].  The vaccine was 
comprised of four different S. aureus strains, one S. agalactiae strain and one S. uberis strain in 
an aluminum hydroxide adjuvant.  Vaccinates were immunized at 8 and 4 weeks pre-calving or 
at 1 and 5 weeks post-calving and controls received a placebo at 8 and 4 weeks pre-calving.  
Cumulative incidence of S. aureus quarter infection in the pre-calving and post-calving 
vaccinated groups were 32.5% and 27.5%, respectively, compared with 75% in the control group 
(P < 0.0001).  A further study [88] evaluated the same vaccine in two commercial Argentine 
dairy herds consisting of 90 cows with a 16% prevalence of S. aureus IMI (herd A) and 85 cows 
with a 15% prevalence of S. aureus IMI (herd B). Vaccinates (dairy A, n = 42; dairy B, n = 40) 
received the vaccine twice four weeks apart. During the four months after vaccination, the 
prevalence of S. aureus IMI in herd A was 9.9% for vaccinates and 15.7% for controls (P < 
0.02). The results for herd B were 4.9% for vaccinates and 8.0% for controls (P < 0.03). Animals 
that were culled from the herds during the study were not considered in the calculation of S. 
aureus IMI prevalence. Hence, this vaccine significantly reduced the prevalence of S. aureus IMI 
within these dairy herds. 
 
Recently, a commercial vaccine has been developed in Israel (Mastivac, National Mastitis 
Reference Center, Bet Dagan, Israel). This vaccine consists of components of three bovine 
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mammary S. aureus strains (VLVL8407, ZO3984 and BS449) in Freund’s incomplete adjuvant 
[89].  Leitner and co-workers [90] tested this vaccine in an experimental bovine intramammary 
challenge trial using cattle from two herds.  Nineteen non-pregnant first and second lactation 
Holstein cattle free of S. aureus IMI were enrolled. In the first herd, five cattle received two 
doses of Mastivac 37 days apart and five cattle served as controls.  Cattle enrolled in the study 
had no detectable antibodies to S. aureus.  All cattle were challenged with 1,000 cfu S. aureus 
(VLVL8409) by intramammary infusion into two mammary quarters 28 days after the second 
vaccination. In the second herd four cattle were vaccinated with Mastivac on days 0, 36 and 56 
of the trial and five cattle served as controls.  Cattle enrolled in the study had no detectable 
serum antibodies against S. aureus.  All cattle in the second trial were challenged with 1,000 cfu 
S. aureus (VLVL8409) by intramammary infusion in two mammary quarters 21 days after the 
final vaccination. Vaccinates in both herds had a significantly decreased incidence of S. aureus 
infected mammary quarters 2 weeks after challenge and increased IgG titers against S. aureus in 
both serum and milk after vaccination when compared with controls.  However, the authors did 
not report cow cure rates nor did they evaluate different IgG subclass titers against S. aureus in 
milk and serum.  A further study [91] evaluated Mastivac in a field setting involving seven herds 
and 452 pre-partum heifers and found that 3 of 228 vaccinates developed S. aureus IMI during 
the subsequent lactation whereas 6 of 224 unvaccinated controls developed S. aureus IMI during 
the same period.  This change was not statistically significant.  A better model may have been to 
study the vaccine in a herd with a high incidence of new S. aureus IMI. 
 
A commercial combination S. aureus and E. coli bacterin has been developed in Spain (Startvac, 
Laboratorias Hipra, S.A., Girona, Spain).  This vaccine does not prevent IMI following 
experimental intramammary challenge with S. aureus, but does decrease bacterial shedding 
following challenge [92].  Studies into this vaccine under field conditions would establish 
whether it may be a useful tool in the control of S. aureus mastitis. 
 
Despite many attempts at vaccination, an effective vaccine against S. aureus has not been 
developed.  An effective vaccine is one which prevents S. aureus IMI, prevents disease as a 
result of S. aureus IMI or prevents shedding of S. aureus from an infected animal.  It has been 
argued that phagocytosis of S. aureus by neutrophils is central to an effective immune response 
17 
 
[93].  Three stages are involved:  neutrophil recruitment [94], opsonisation of S. aureus by 
immunoglobulins and complement [95] and ingestion and killing of S. aureus.  One might 
therefore assume that developing a strategy to enhance each of these stages would ensure 
prevention of S. aureus IMI.  Several disadvantages to this approach exist.  Bulk milk SCC is 
used as a monitor of udder health and milk quality [16].  Increases in SCC result in producers 
incurring financial penalties.  An increase in neutrophil recruitment would inevitably lead to 
increased SCC.  Opsonization of S. aureus is inefficient in the mammary gland.  In normal milk, 
IgG1 predominates due to active transport into the mammary gland but the bovine neutrophil 
does not possess an IgG1 receptor [96].  Other antibody isotypes only enter the gland in higher 
amounts when the blood-milk barrier breaks down, such as in cases of mastitis [93].  Neutrophils 
in milk are less able to phagocytose and kill pathogens than those in serum due to large numbers 
of fat globules [97].  Given the lack of an effective S. aureus vaccine, several novel control 
measures have been proposed. 
 
3.3.3 Alternate control measures 
Therapeutic cessation of lactation is a method by which a mammary quarter is chemically treated 
to prevent any further milk production and bacterial shedding from that quarter.  If a S. aureus 
infected quarter is no longer lactating, it is no longer a reservoir of infection in the dairy herd.  
Chlorhexidine and povidone iodine were compared in a study of mid- to late lactation cattle with 
single quarter S. aureus IMI [98].  Lactation ceased permanently in all seven of the quarters 
treated with povidone iodine whereas five of the seven quarters treated with chlorhexidine 
produced milk during the subsequent lactation.  A subsequent study [99] reported that 
chlorhexidine is able to be recovered from milk up to 42 days following treatment and was 
therefore not considered a practical treatment.  No study on the elimination kinetics of povidone 
iodine was performed. 
 
Staphylococcus aureus may enter the herd in dairy heifers that have not been milked [100].  The 
source of these infections may be flies since herds that practise fly control had a dramatically 
lower prevalence of S. aureus IMI than those which did not [100].  Owens and coworkers [101] 
reported that horn flies (Haematobia irritans) were able to become colonized with S. aureus and 
remain colonized for 96 hours following exposure to teats of dairy heifers with S. aureus IMI.  
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Given that heifers harbouring a S. aureus IMI may have S. aureus present at other body sites 
[102], fly control may be a method of reducing S. aureus IMI in the dairy herd. 
 
Intramammary devices are coiled polyethylene devices that are inserted into the lactiferous sinus 
of the mammary gland [103].  The presence of an intramammary device significantly reduced the 
incidence of S. aureus IMI but increased milk SCC following experimental intramammary 
challenge in one study [103].  A different study [104] reported that, if the quarter SCC following 
administration of the intramammary device was less than 10
6
/ml, S. aureus IMI was not 
prevented but if the quarter SCC was greater than 10
6
, only 17% of challenged quarters 
developed S. aureus IMI.  However, given that producers are paid premiums for milk of low 
SCC, the intramammary device has little potential as a control measure in a commercial 
situation. 
 
Attempts have been made to prevent S. aureus IMI by generating animals that are transgenic for 
lysostaphin.  The initial work focused on generating mice that secreted an active form of 
lysostaphin into milk.  Lysostaphin is normally produced by S. simulans and becomes 
glycosylated when produced by eukaryotic cells.  Therefore, a bioactive lysostaphin variant (Gln 
(125,232)-lysostaphin) was generated, was active in milk and did not affect milk protein [105].  
Jersey cattle transgenic for lysostaphin were generated and were significantly more resistant to 
infection than non-transgenic animals [43].  Milk protein was unaffected by the presence of 
lysostaphin. 
 
3.4 Bovine mammary responses to Staphylococcus aureus 
3.4.1 Physical barriers to infection 
The first physical barrier that a mammary pathogen will encounter is the teat canal.  Given that 
the teat canal may be colonized by a number of different organisms [106], the ability of the teat 
canal to prevent entry of bacteria into the mammary parenchyma appears critical in preventing S. 
aureus IMI.  Opening of the teat canal before calving has been reported as an important 
development of mastitis [107].  Closure of the teat canal when the animal is not milking is 
maintained by a muscular sphincter and a keratin plug [108].  Increased milk flow rate through 
the teat canal and decreased teat canal length are associated with increased risk of IMI [109].   
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Damage to the teat canal orifice increases the risk of IMI with S. aureus [110].  If cows were 
milked without pulsation, the risk of IMI was significantly increased as was teat canal diameter 
[111].  Teat canal keratin contains myristic, palmitoleic, and linoleic acids that inhibit bacterial 
colonization of the teat canal [112].  The importance of these fatty acids was demonstrated by 
Capuco and coworkers [113] who demonstrated increased susceptibility of lactating Jersey cows 
to IMI with the contagious pathogen S. agalactiae when teat canal keratin was removed.   
 
3.4.2 Innate immune responses 
Complement is a major humoral innate factor that is involved in the innate immune responses to 
pathogens.  The complement system consists of two pathways, classical and alternative.  Studies 
on S. agalactiae have revealed that the alternative pathway predominates in the mammary gland 
whilst the classical pathway is not active due to the absence of C1q [114].  The alternative 
pathway is dependent on a constitutive level of C3 hydrolysis which provides C3b which is able 
to bind the surface of pathogens and subsequently complex with factors B and D to form a C3 
convertase.  This leads to a positive feedback loop and increased C3 hydrolysis.  The level of C3 
in milk is approximately 2.5% that of serum [114].  However, C3 does not appear to enhance the 
opsonisation and phagocytosis of S. aureus by neutrophils [115].  The complement factor C5a is 
involved in chemotaxis of neutrophils to the site of inflammation [94].  However, IMI with S. 
aureus results in low levels of C5a in the mammary gland [116], limiting the migration of 
neutrophils into the gland.  Based on this evidence, complement alone does not appear to be 
important in bovine mammary responses to S. aureus. 
 
Lactoferrin has already been discussed as a novel treatment strategy for S. aureus.  Increased 
expression of the lactoferrin gene from bovine mammary epithelial cells is associated with a 
decreased susceptibility to mastitis [117].  Lactoferrin expression is increased 24 hours after IMI 
with S. aureus [118] with lactoferrin concentration appearing to correlate with milk SCC [119].  
The susceptibility of S. aureus to lactoferrin is strain dependent therefore lactoferrin may be 
effective in some cases but not in others [41, 120].  The interaction between S. aureus and 
lactoferrin is dependent on specific cell surface receptors.  Given that a subset of S. aureus 
isolates do not express lactoferrin receptors [121], the strain dependent effects may be due to the 
presence or absence of these receptors.  Lactoferrin may also affect mammary immune responses 
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through the augmentation of other immune processes.  Specifically, lactoferrin appears to permit 
the deposition of C3 on the surface of S. aureus and enhances subsequent complement-mediated 
killing [122]. 
 
Transferrin is another iron-binding protein which is present in milk in low concentrations 
although the concentration is higher in colostrum or in mastitic milk which suggests transudation 
of transferrin from blood into the mammary gland [123].  This is supported by evidence which 
shows that transferrin is not synthesized in the mammary gland of sheep whereas it is 
synthesized in the mammary glands of other nonruminant species [124].  Given the lack of 
synthesis in sheep, it is likely that transferrin is not synthesized in the bovine mammary gland.  
Also, the low transferrin concentrations suggest that it is not an important defence against S. 
aureus. 
 
Lysozyme is a bactericidal peptide which targets bacterial cell wall peptidoglycans.  It is able to 
potentiate the ability of lactoferrin to kill S. aureus [125].  In sheep, high milk lactoferrin and 
lysozyme concentrations are associated with decreased recovery of S. aureus from the mammary 
gland following experimental IMI [126].  In cattle, lysozyme levels appear to drop during S. 
aureus IMI [127] suggesting that it can be overwhelmed in the face of an active IMI. 
 
Natural antibodies are produced in response to normal environmental antigens rather than 
specifically against foreign pathogens [128].  Natural antibodies against melibiose are present in 
cattle and appear able to react with the contagious mastitis pathogen S. agalactiae [129] 
suggesting that they may have a protective role in bovine mastitis.  Unfortunately, the ability of 
these antibodies to recognize S. aureus has not been investigated. 
 
Toll-like receptors are a class of receptors that recognize pathogen-associated molecular patterns 
(PAMPs).  They appear to have a threefold role.  They allow for specific recognition of 
pathogens by the innate immune system, they act as a bridge between innate and adaptive 
immunity and they may provide a mechanism for pathogens to avoid protective host responses 
[130].  Toll-like receptors that are involved in the recognition of S. aureus include TLR2 which 
binds bacterial peptidoglycan and TLR9 which binds bacterial CpG DNA [108].  The roles of 
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TLRs as a bridge between innate and adaptive immunity as well as the mechanisms by which 
they may be used by pathogens to avoid protective host responses will be discussed in the section 
on adaptive immunity. 
 
Few neutrophils are present in the uninfected mammary gland [131].  Neutrophils traffic to the 
mammary gland in response to cytokines released by macrophages and T lymphocytes [94].  
Neutrophils exert antibacterial effects through phagocytosis, production of superoxide radicals 
[132] and small antimicrobial peptides called defensins [133].  Mammary neutrophils have 
impaired phagocytic and pathogen killing ability when compared with those in blood [134] due 
to the presence of large amounts of fat and casein and low amounts of glucose in milk [97, 135].  
Despite all of these factors, the ability of neutrophils in the mammary gland to prevent S. aureus 
IMI has been discussed.  However, the presence of large numbers of neutrophils in the gland 
does increase milk SCC and is therefore unacceptable to the producer. 
 
Macrophages are the major cell type in the noninfected or nonlactating mammary gland [136].  
They are phagocytic cells which can ingest and kill pathogens although their phagocytic activity 
is decreased in mammary gland compared to blood [137] and is decreased compared to 
mammary neutrophils [137].  Their major role is likely to be as part of the adaptive immune 
response and they will be reviewed in detail in that section. 
 
Mammary epithelial cells are an important cell type in the response to mastitis as they are in 
direct contact with invading pathogens.  Mammary epithelial cells express TLR2 and TLR4 and 
the expression of these genes appears to be unaffected by exposure to their respective ligands, 
lipoteichoic acid and lipopolysaccharide [138].  Mammary epithelial cells are able to secrete 
chemokines.  Exposure of primary mammary epithelial cells to S. aureus resulted in a dose and 
time dependent stimulation of IL-8, IL-1β, TNF-α, TGF-β1 and IL-10 [139, 140].  The responses 
also appeared to be strain dependent [140].  Expression of inflammatory proteins is dependent on 
the transcription factor NF-κB.  Increased NF-κB has been reported in cattle with chronic IMI 
[141].  A study using the bovine mammary epithelial cell line, MAC-T, revealed that prolactin 
can promote cytokine expression by MAC-T cells by means of an increase in NF-κB [142].  
Other evidence suggests that S. aureus fails to activate Nf-κB in mammary epithelial cells 
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despite activation of TLR-2 and TLR-4 although one might question the mechanism by which S. 
aureus activates TLR-4 in this model [143].  It is clear that mammary epithelial cells can both 
recognize and respond to pathogens as part of the innate immune response. 
  
Inducible nitric oxide synthase (iNOS) is an enzyme that is produced by bovine mammary 
epithelial cells and bovine leucocytes in response to inflammatory stimuli [144].  It has been 
proposed to be a scavenger of ROIs such as peroxynitrite and thus prevents excessive damage to 
tissues as a result of neutrophil oxidative burst [145].  Inhibition of iNOS during inflammatory 
responses in vitro did not affect neutrophil migration or ROI production [146].  This evidence 
suggests that iNOS does not have a major role in the innate response to IMI. 
 
Antimicrobial peptides are components of the innate immune system that have antimicrobial 
activity against pathogens as well as serving as chemoattractants for immune cells.  Early work 
revealed that the bovine tracheal antimicrobial peptide (TAP), a member of the β-defensin class, 
is active against many pathogens including S. aureus [147].  It has been shown that many β-
defensin genes are expressed in the mammary gland [148] and β-defensin expression in the 
mammary gland is increased during mastitis [149].  This is contrasted by the lack of upregulation 
of cathelicidin expression in vivo during mastitis although cathelicidin expression is increased 
when bovine neutrophils are exposed to LPS [150].  Furthermore, cathelicidins possess 
antibacterial activity against S. aureus [150].  A recent study has characterized antimicrobial 
peptide expression in the entire bovine mammary gland [151].  Constitutive expression of lingual 
and tracheal antimicrobial peptides was present in the region of the SMLN, β-defensin 1 
expression was localized to the cisternal epithelium and the Rosette of Furstenburg and the 
expression of psoriasin was located at the teat canal [151]. 
 
Serum amyloid A (SAA) is an acute phase protein that was first isolated from the milk of a cow 
suffering from acute mastitis [152].  Further studies revealed that it was present in milk in 
increased concentrations during mastitis, including mastitis that was caused by S. aureus [153-
155].  More recent work has characterized expression of mRNA encoding the SAA3 protein.  
The protein is expressed by mammary epithelial cells at moderate levels during late pregnancy, 
at low levels during lactation, and moderate to high levels following dry-off and at high levels 
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during mastitis [156].  Given that SAA is able to enhance the antimicrobial activity of 
neutrophils [157], it may play an important role in the innate response to S. aureus. 
 
3.4.3 Adaptive immune responses 
Antigen recognition is the initial stage of the adaptive immune response.  Pathogens are 
recognised by antigen presenting cells such  as mammary macrophages [158] and B cells [159].  
Dendritic cells are likely to be involved in antigen presentation from the mammary gland but this 
has not been studied.  In fact, only one study has reported the presence of DCs in the bovine 
mammary gland [160].  Based on evidence in other species, immature DCs efficiently take up 
antigen and monitor the environment for danger signals [161].  Endogenous protein antigens are 
ubiquitinated, degraded by the proteasome into small antigenic peptides which are loaded onto 
MHC class I in the endoplasmic reticulum which is then displayed at the cell surface [162].  
Antigens presented on the cell surface can then be recognised by CD8+ T cells.  Exogenous 
protein antigens are taken up using receptor mediated endocytosis [161].  Once antigens have 
been internalized, they can either be processed for binding to either MHCII or MHCI.  Antigens 
internalized for loading onto MHCII are degraded in endosomes and lysozomes into small 
peptides which are then loaded onto the MHCII molecule [150].  Antigens internalized for 
loading onto MHCI undergo a process known as cross-presentation.  Cross-presentation takes 
place in the endoplasmic reticulum, allowing MHCI loading with antigenic peptides [163].   
 
Antigen presentation alone is insufficient for DC maturation and migration to the local lymph 
node.  A danger signal should also be present.  Danger signals include products of inflammation 
as well as pathogen-associated molecular patterns (PAMPs).  Products of inflammation that act 
as danger signals include CD40L, TNF-α, IL-1, IL-6 and IFN-α [163].  These activate TLRs 
which enable DC maturation, their migration to the draining lymph node and the can affect the 
bias of T cell responses [163-166].  
 
The major controllers of adaptive immunity are T lymphocytes.  Traditionally, T cell responses 
can be classified according to the bias of CD4+ T cells.  Cell mediated immunity is driven by 
TH1 cells that secrete IFN-γ and humoral immunity is driven by TH2 cells that secrete IL-4 and 
IL-5 [167].  Furthermore, IFN-γ appears to drive the production of IgG2 whilst IL-4 appears to 
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drive the production of IgG1 [168].  A TH1 response is thought to be more important in the 
elimination of intracellular pathogens [169, 170] whilst a TH2 response is thought to be more 
important in the elimination of extracellular pathogens [169].  Historically, the two types of 
response have been considered to be mutually exclusive [171].  However, more recent work 
suggests that a spectrum of immune responses occurs with TH1 and TH2 responses at both poles.  
For example, effective immunity to the pathogenic stage of the malarial life cycle in mice 
requires both TH1 and TH2 responses [172].  The heterogeneity of bovine responses is illustrated 
by reports that up to 94% of T cell clones isolated from cattle infected with F. hepatica 
expressed both IL-4 and IFN-γ [173].  Hence, studies of the CD4+ T cell response to infection 
must determine the contribution of both TH1 and TH2 responses. 
 
A third type of T cell is known as the regulatory T cell.  Regulatory or suppressor T cell 
populations have been reported as far back as the 1970s [174].  Since then, several populations of 
T cells with regulatory capacities have been described including CD4+ CD25+ Foxp3+, CD3+ 
CD4- CD8- (DN), CD8+ CD28- and type 1 (Tr1) regulatory T cells as well as Th3 and NKT 
cells [175].  The CD4+ CD25+ Foxp3+ regulatory T cells are the best understood subset.  These 
have been known as naturally-occurring regulatory T cells as they were first described as an 
endogenous population involved in peripheral immunologic tolerance based on reports that 
mutations in the Foxp3 gene in humans and mice resulted in autoimmune disease [176, 177].  
For example, removal of the thymus in 3-7 day old mice results in autoimmune disease that can 
be prevented by the adoptive transfer of CD4+ CD25+ T cells [178], suggesting that they 
develop in the thymus early in life.  Regulatory T cells may also be induced in response to 
inflammation and regulate the magnitude of the inflammatory response.  These are known as 
adaptive regulatory T cells [179].  Adaptive regulatory T cells include all the classes described 
above, including CD4+ CD25+ Foxp3+ T cells [180].  Adaptive regulatory T cells can circulate 
through lymphoid tissues and can traffic to a site of inflammation [181].  They may be generated 
from other classes of T cell [182]. 
 
The mechanism of regulatory T cell action is poorly understood.  It does appear that blocking of 
CTLA-4 partially blocks immune tolerance [183] and that anti-TGFβ treatment or the use of IL-
10(-/-) mice removed the suppressive effects of naturally-occurring regulatory T cells on airway 
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hypersensitivity in a murine model [184].  These data suggest that naturally-occurring regulatory 
T cells act by means of direct cellular interactions mediated by CTLA-4 and by the cytokines 
TGFβ and IL-10.  Adaptive regulatory T cells appear to act in a more cytokine-dependent 
manner [179]. 
 
To date, reports on regulatory T cell populations in the bovine mammary gland have been 
limited.  Their presence has been proposed as mammary immunity has been reported to be less 
efficient than that of other body systems.  Decreased mammary immunity is manifest as 
decreased activity of mammary neutrophils compared to peripheral blood neutrophils [185], poor 
antigen presentation in the mammary gland [7] and a poor blastogenic response of milk 
lymphocytes to stimulation [186].  The poor blastogenic response of milk lymphocytes is 
particularly apparent during the postpartum period [187].   
 
Studies have focused on mechanisms behind the poor blastogenic response of milk lymphocytes.  
Park and co-workers [188] reported that cows that were susceptible to mastitis had CD4:CD8 T 
cell ratios of less than one in mammary secretions and peripheral blood, suggesting that these 
cell populations play a role in susceptibility to bovine mastitis.  The increase in the proportion of 
mammary CD8+ T cells was attributed to the presence of CD8+ ACT2+ T cells [189].  Shafer-
Weaver and Sordillo noted that CD8+ T cells isolated from the mammary gland during the 
immediate post-partum period had no cytotoxic activity despite a high level of activation [187].  
Enrichment of cell cultures with these CD8+ T cells decreased the proliferative activity of CD8+ 
cells in the cultures.  They concluded that these were suppressor T cells.  Hence, a population of 
regulatory T cells appears to be present in the uninfected mammary gland and these may have a 
role in the pathogenesis of IMI. 
 
Dendritic cells are thought to be crucial in the development of the bias of T cell responses.  For 
example, IL-12 secreted from DCs is able to induce a TH1 phenotype in CD4+ cells [190].  The 
action of IL-12 appears to be enhanced by the presence of IL-18 [191] and ICAM-1 [192].  
Induction of a TH2 phenotype is less well understood.  Interleukin-4 is required for generation of 
TH2 responses [193].  Furthermore, secretion of IL-4 by murine T cells is enhanced by the 
presence of MCP-1 [194] and the OX40 ligand [195].   
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Whilst naturally-occurring regulatory T cells are generated in the thymus in the immediate 
postpartum period and are involved in self-tolerance [176, 177], DCs appear to be central in the 
induction of adaptive regulatory T cells.  The first evidence of this came from a report that 
exposure of CD4+ T cells to IL-10 resulted in generation of cells with a regulatory phenotype 
[196].  Recent evidence suggests that stimulation of T cell clones by immature DCs results in T 
cell tolerance, most likely as a result of T cell anergy caused by a lack of co-stimulation [197].  
Dendritic cells can also secrete cytokines such as IL-10 and TGFβ and may express members of 
the B7 family and members of the Notch signalling pathways to induce a regulatory T cell 
phenotype [198]. 
 
The bias of DCs themselves is mediated by several factors.  Exposure to moderate amounts of 
antigen leads to TH1 responses whereas exposure to high or low amounts of antigen leads to TH2 
responses [199].  A high DC to T cell ratio also leads to mixed TH1 and TH2 responses whereas a 
low DC to T cell ratio leads to TH2 responses [200].  Dendritic cell mediated T cell polarization 
can be altered by the presence of a pathogen.  For example, presentation of Mycobacterium bovis 
antigens by DCs of immunologically naïve calves resulted in the induction of a TH1 response 
[201].  Furthermore, infection of DCs by M. bovis resulted in the secretion of IL-12 and IL-18 
[164].  Pathogens such as Bordetella pertussis can, in humans, induce the generation of adaptive 
regulatory T cells [202].  These effects may be mediated by activation of TLRs on DCs.  Many 
TLRs are involved and different DCs can respond differently to TLR stimulation.  However, it is 
generally considered that TLR-3, -4, -5, -7 and -9 are involved in the induction of TH1 responses 
whilst TLR-1, -2 and -6 are involved in the induction of TH2 responses [165]. 
 
Dendritic cells can be isolated from the afferent lymph of cattle based on the selective expression 
of the DEC-205 surface antigen [203] and are able to be separated into one of two populations 
based on expression of the SIRPα surface molecule [204, 205].  It has been suggested that, as 
SIRPα+ cells secrete high levels of IL-10 and variable levels of IL-12 and SIRPα- cells secreted 
higher levels of IL-12, SIRPα+ cells may induce a balanced T cell response whilst SIRPα- cells 
may induce a predominantly TH1 response [164].  Hence, DCs from the afferent lymph of dairy 
cattle may be able to polarize the T cell response.  However, no work has been performed on 
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mammary DCs so far.  Studying DCs and their role in bovine mastitis is an interesting and 
important area. 
 
Several studies have reported the effects of S. aureus IMI on cellular immune responses.  Studies 
that report the effects of superantigens are discussed in section 3.5.7.  Soltys and Quin reported 
that numbers of CD4+ T cells in milk increased significantly in response to S. aureus IMI [206].  
Gronlund and coworkers reported that the proportions of CD4+ and CD8+ T cells in milk 
decreased during the acute phase of S. aureus IMI but recovered during the chronic phase.  The 
proportion of B cells increased at all stages of S. aureus IMI, leading the authors to propose that 
S. aureus causes humoral immune responses to occur in the mammary gland [207].  When cattle 
were experimentally infected with S. aureus, the number of CD4+ T cells in milk increased in 
the early stages of infection and was negatively correlated with bacterial recovery from milk 
[208].  The same group also reported a decrease in CD3+ cells and an increase in CD11b+ cells 
in milk following experimental S. aureus IMI [209].  However, the study reported percentages of 
cells identified by flow cytometry so these results probably reflect an influx of neutrophils into 
the mammary gland following infection.  Somewhat paradoxically, the same group reported that 
the number of CD3+, CD4+ and CD8+ cells decreased in the milk of animals following 
experimental S. aureus IMI [210].  Park and coworkers reported that proliferative responses of 
milk CD4+ T cells from cattle with S. aureus IMI was decreased when compared with uninfected 
animals.  When a population of CD8+ T cells expressing the ACT2 activation marker was 
removed from cell cultures, proliferative responses in infected animals were increased.  
Restoration of CD8+ ACT2+ T cells to cell cultures decreased proliferative responses in a dose-
dependent manner [7].  This is evidence for the existence of regulatory T cell populations being 
induced in response to S. aureus IMI. 
 
Leitner and coworkers reported that the proportions of CD4+ and CD8+ T cells increased in the 
milk of animals with chronic but not acute S. aureus IMI [211].  A follow-up study from the 
same group reported that T cell populations in the SMLN did not vary between animals with S. 
aureus IMI and controls.  In uninfected mammary parenchyma, the predominant T cell 
population was CD8+ and this was enhanced following S. aureus IMI [212]. 
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Riollet and coworkers studied cell populations and cytokine expression in milk following S. 
aureus IMI [6].  They reported that CD8+ T cells and B cells were recruited into the milk 
following infection, suggesting a balanced immune response.  Furthermore, infection resulted in 
increased IL-1α, IL-1β, IL-6, TNF-α, IL-10 and IL-12 expression in cells isolated from the milk 
of infected mammary glands whilst IL-2 and IL-4 mRNA was not present.  This evidence 
supports a TH1 and a regulatory T cell response in milk.  Lee and coworkers studied the 
expression of IL-6, IL-8, IL-12, GM-CSF, TNF-α and IFN-γ in cells from the milk of animals 
infected with either S. aureus or E. coli [213].  They reported that large variation existed between 
animals.  Increases in all cytokines were reported for both infections with the exception of IFN-γ 
following S. aureus IMI.  However, the magnitude and speed of onset of the response to S. 
aureus was diminished compared with that for E. coli.  The authors therefore suggested that the 
decreased responses to S. aureus may explain the chronic nature of S. aureus IMI.  These results 
are supported by evidence which showed that IL-1β, IFN-γ, IL-12, and IL-10 in milk were 
upregulated in the acute phases of E. coli and S. aureus IMI but the magnitude of the increases 
was lower for S. aureus [4].  A different study reported that milk IFN-γ, IL-12, TGF-α and TGF-
β all increase during the first 24-36 hours following S. aureus IMI [5].  A recent study reported 
that cytokine gene expression is induced as a result of S. aureus IMI in dairy goats.  Specifically, 
IL-1α, IL-2 and CXCL6 were upregulated during the acute phase of infection [214].  Work in 
cattle has shown that, during chronic S. aureus IMI, expression of IL-2, IL-12, IL-15 and IL-18 
is upregulated in PBMCs and expression of IL-17 is upregulated in milk somatic cells [215]. 
 
3.5 Staphylococcus aureus virulence factors involved in immune evasion 
3.5.1 Capsular polysaccharide 
Staphylococcus aureus produces a polysaccharide capsule which may be expressed by up to 
100% of bovine mammary isolates [70].  In the same study, almost all of the isolates could be 
classified as possessing capsular serotypes 5, 8 and 336.  Kampen and coworkers [216] 
constructed isogenic variants of a single S. aureus strain expressing no capsule, CP5 or CP8.  
The presence of the capsule inhibited killing of S. aureus by bovine neutrophils in vitro through 
downregulation of oxidative burst.  This effect was reversed by the presence of antibodies 
against CP5 or CP8.  This evidence suggests that capsule is an antiphagocytic factor that 
prevents killing by neutrophils but does not prevent opsonisation of bacteria.  Capsular 
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polysaccharide is also a T cell independent antigen therefore stimulates immune responses in the 
absence of antigen presentation and T cell help [217].  This means that responses will only be 
stimulated by mature B cells that produce antibodies that recognise the CP.  If an animal does not 
possess these B cells in the mammary gland, it is unlikely that a response will be mounted.  
Therefore capsule disrupts both innate and acquired immune responses. 
 
3.5.2 Fc receptors 
Protein A is a virulence factor that can bind to the Fc region of immunoglobulins [218] thus 
preventing recognition of opsonized bacteria by Fc receptors present on phagocytic cells.  
However, the role of protein A in the pathogenesis of S. aureus mastitis is controversial. 
Experiments in a murine mastitis model reported that the virulence was not affected by protein A 
[219].  A recent study used linear regression models to associate the presence or absence of 
virulence genes with the inflammatory response of the bovine mammary gland [220].  The 
presence of the protein A gene was associated with chronic subclinical mastitis.  This evidence, 
obtained in dairy cattle, suggests that protein A is indeed a major factor in the evasion of bovine 
mammary immune responses. 
 
3.5.3 Invasion of epithelial cells 
Staphylococcus aureus is able to avoid humoral immune responses by becoming intracellular.  
Electron microscopy revealed that S. aureus can enter bovine mammary epithelial cells in 
primary culture [65].  Invasion was shown to involve F-actin polymerization and therefore the 
cytoskeleton.  Fibronectin-binding protein (FnBP) is involved in this process and is thought to 
interact with heat shock protein 60 and integrins [221] although work in a mouse model showed 
that removal of FnBP only delayed invasion [222].  Recent work has shown that internalization 
of S. aureus into bovine endothelial cell is promoted in the presence of TNF-α and IL-1β with 
the effects being reversed by inhibition of NF-κB nuclear translocation [223].  Internalization 
may be induced by an inflammatory response and therefore may represent an adaptation of S. 
aureus to avoid inflammatory responses.  However, it is important to remember that internalized 
bacteria still undergo antigen presentation through MHCI and can be cleared by the action of 
CD8+ TC cells. 
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3.5.4 Small colony variants 
Small colony variants (SCV) of S. aureus are variants which form slow growing pin-point 
colonies on agar.  They were originally identified as dwarf colony variants when isolated from 
cases of bovine mastitis [224].  Mutation of the hemB gene of the S. aureus Newbould 305 strain 
results in the generation of a SCV.  This variant possesses the same susceptibility to cephapirin 
treatment but is less able to colonize murine mammary glands than the wild type variant in vitro 
but is better able to persist in murine mammary glands treated with cephapirin in vivo [225].  
Small colony variants have been isolated from chronic cases of bovine mastitis [226] and seem 
to cause a mild, persistent IMI [226, 227] when compared with conventional variants.  The 
decreased susceptibility of SCVs to conventional antimicrobial agents has been demonstrated in 
cattle and has been associated with an intracellular location of bacteria [228].  The intracellular 
location may also assist SCVs in avoiding host defences. 
 
3.5.5 Cytotoxins 
Staphylococcus aureus secretes a variety of virulence factors that are cytotoxic.  For example, α-
toxin is a cytolysin which forms transmembrane pores in host cells [229].  However, this can 
affect all cells and is therefore not specifically involved in immune evasion.  Similarly, β-toxin is 
more involved in damage to mammary parenchyma rather than immune evasion [230].  One 
virulence factor of interest is leucocidin.  It is expressed by over 90% of bovine mammary S. 
aureus isolates [231] and its presence is associated with increased mammary inflammation [232].  
It forms transmembrane pores in mammary leucocytes and their subsequent death [233] and is 
considered the most active leukotoxin for bovine neutrophils [234].  This evidence implicates 
leucocidin in the direct disruption of bovine neutrophils and so is a factor enabling S. aureus to 
evade innate responses. 
 
3.5.6 Biofilms 
Costerton and coworkers defined biofilms as: “A structured community of bacterial cells 
enclosed
 
in a self-produced polymeric matrix and adherent to an inert or
 living surface” [235].  
This community of cells shows increased resistance to treatment with antibiotics, host defenses 
and disinfectants [236].  Formation involves the binding of cells to a surface followed by cell 
multiplication.  Cells are attached to one another by extracellular polysaccharides.  Staphylococci 
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may also secrete a glycocalyx layer (slime) [236].  Biofilms appear to be referred to as 
“pseudocapsule” in several studies of bovine mastitis [237].  Bovine mammary S. aureus isolates 
have been shown to form biofilms when grown in vitro in milk [238].  Staphylococcus aureus 
strains obtained from milk were more likely to produce biofilm than those obtained from teat 
skin or milking equipment [239].  “Pseudocapsule” has been shown to be produced when S. 
aureus strains are grown in the bovine mammary gland [240].  Antibodies against 
“pseudocapsule” opsonised S. aureus for phagocytosis by neutrophils [241].  Biofilms appear to 
have a major role in S. aureus mastitis and, given their previously mentioned effects on host 
defense, are likely to shield bacteria from all aspects of host responses. 
 
3.5.7 Superantigens 
Up to 21 different staphylococcal enterotoxins have been characterized [242].  Whilst it is 
impractical to discuss each toxin individually, mutational analysis reveals that staphylococcal 
enterotoxins may act as either direct gastrointestinal toxins or as superantigens [243].  The direct 
gastrointestinal effects are poorly understood.  However, S. aureus is able to interact directly 
with epithelial cells.  A study using renal tubule epithelial cells revealed that proximal tubule 
epithelial cells undergo apoptosis following treatment with staphylococcal enterotoxin B [244].  
Whether enterotoxin has similar effects on intestinal cells is unclear.   
 
The superantigen effects of S. aureus are far better understood.  The enterotoxin forms a 
complex with the MHCII molecule.  The complex binds to the variable region of the T cell 
receptor β chain [245].  The need for a specific peptide antigen to activate T cells is therefore 
removed, allowing massive T cell stimulation [246].  The stimulated T cells secrete many 
cytokines at toxic levels with the three most important being IL-2, IFN-γ and TNF-α [247].  The 
high cytokine levels cause severe systemic clinical signs consistent with a toxic shock syndrome.  
Evidence also exists that staphylococcal enterotoxins can stimulate bovine γδ T cells in a CD86 
and IL-2 dependent manner [248] although the relevance of this remains to be determined.   
Staphylococcal enterotoxin C is a superantigen encoded on the SapIbov pathogenicity island of 
S. aureus [249] that can activate T cells by cross-linking MHC with the T cell receptor (TCR) 
[250].  It is expressed by approximately 10% of bovine mammary S. aureus isolates [86] and 
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despite its relatively low prevalence; it has several biological effects including the induction of T 
cell anergy [251] and deletion [252], toxic shock syndrome [253] and autoimmune disease [254]. 
It was reported that exposure of bovine PBMCs in culture to SEC induced a state of partial 
activation of CD4+ T cells [255] as well as the genesis of a population of CD8+ CD26+ T cells 
[255, 256].  Furthermore, exposure of bovine PBMCs to SEC results in low levels of nucleic acid 
synthesis compared to human PBMCs used as controls [257].  More recent work compared cows 
that were susceptible to mastitis and those which tended to be resistant.  It appears that 
susceptible cows possess a certain MHC haplotype and have a CD4+:CD8+ T cell ratio of less 
than one [188].  It was hypothesized that the decreased ratio was as a result of the presence of 
CD8+ ACT2+ T cells which possessed a regulatory function [258].  This hypothesis was 
investigated further by exposing bovine PBMCs in vitro to SEC.  Exposure to SEC was reported 
to increase the proliferation and decrease the apoptosis of CD8+ T cells [257] although the role 
of ACT2 was not evaluated.  A more recent study involved exposing peripheral blood of dairy 
cattle to SEC.  Exposure to SEC increased the proliferation of CD8+ T cells compared with 
CD4+ T cells [8].  Furthermore, CD4+ CD25+ Foxp3+ T cells which transcribed IL-10 and 
TGFβ were induced in response to SEC [8].  Stimulation of bovine PBMCs with SEC can also 
cause IL-10 secretion [259], further supporting the hypothesis that SEC is involved in the 
generation of regulatory T cells.  However, the study [259] did not evaluate the specific cellular 
source of IL-10. 
 
Despite the aforementioned evidence, the relevance of regulatory T cells in the mammary gland 
is controversial.  Ebling and coworkers studied three groups of cattle, those infected with S. 
aureus expressing SEC, those infected with S. aureus that did not express SEC and uninfected 
controls [260].  No difference existed between any of the groups regarding the CD4+:CD8+ T 
cell ratio.  Also, the number of CD8+ ACT2+ T cells increased following IMI with the S. aureus 
strain that did not express SEC but did not change following IMI with the S. aureus strain 
expressing SEC [260].  One potential explanation for the difference between the studies may be 
that Ebling and coworkers [260] studied cellular immunity in milk.  Cellular immunity in 
mammary tissue and the regional lymph nodes may be different.  Based on this apparent 
contradictory evidence, the role of SEC in the mammary gland needs to be explored further. 
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Since S. aureus is able to enter bovine mammary epithelial cells [222], a TH1 response would be 
likely to clear S. aureus IMI.  Previous work suggests that an IgG2 response in milk may protect 
against S. aureus IMI [95, 261, 262], supporting the hypothesis that a TH1 response would be 
protective.  However, culture of bovine PBMCs in the presence of SEC leads to sustained 
production of IL-4 and IL-13, but only transient production of IFN-γ, IL-2 and IL-12 [257, 259], 
suggesting that exposure to SEC induces a TH2 response in the mammary gland. 
Despite its biological effects, the prevalence of S. aureus strains expressing SEC is relatively low 
in the bovine mammary gland.  However, evidence exists that S. aureus strains vary in their 
ability to cause disease and avoid mastitis control procedures [55, 263].  The presence of SEC 
may therefore explain why some strains are better able to cause disease and avoid mastitis 
control.  Despite the current evidence, the effects of SEC on bovine mammary immunity are not 
entirely clear. Specifically, the majority of studies have been carried out in mammary secretions 
or using cultured PBMCs.  Future studies should focus on the effects that S. aureus and SEC 
have in vivo and focus on responses in mammary tissue and in the regional lymph nodes. 
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4.  MATERIALS AND METHODS 
 
4.1 Animals and treatments 
Animals used in all experiments were housed in the animal care facility at VIDO.  They were 
housed in accordance with good animal care and husbandry practises as defined by the Canadian 
Council on Animal Care and were provided with full veterinary care.  Furthermore, experimental 
protocols were approved by the University of Saskatchewan Animal Care Committee. 
 
4.1.1 Cattle as peripheral blood mononuclear cell donors 
For studies involving responses to SEC, four castrated male mixed breed beef cattle were 
sourced from the VIDO research farm.  Animals were selected based on low serum titres against 
S. aureus and staphylococcal enterotoxin C (SEC) (table 4.1).  Serum titres represent humoral 
immunity to S. aureus and SEC.  For studies examining cytokine production by peripheral blood 
mononuclear cells (PBMCs) in response to S. aureus in vitro, dairy cows were sourced from the 
University of Saskatchewan Greenbrae Herd.  Lactating dairy cows with recall responses to S. 
aureus were selected as they were presumed to possess memory T cells specific for S. aureus.    
The existence of recall responses was based on high serum antibody titres against S. aureus and 
large proliferative responses to staphylococcal alpha toxin (stimulation index greater than 100) 
(table 4.2).  Animals also had a current or previous S. aureus IMI confirmed by milk culture.  To 
perform milk cultures, milk was aseptically collected from each udder half.  Milk was plated 
onto TSA and incubated for 48 hours at 37°C in the presence of 5% CO2.  If no bacterial growth 
was observed following 48 hours of incubation, the culture was considered to be negative.  If 
colonies were observed, they were subjected to Gram staining and their Gram staining 
characteristics recorded. 
 
Blood samples for serum titres were collected into serum separator vacutainer collection tubes 
(BD Vacutainer SST ®, Franklin Lakes, NJ, USA), allowed to coagulate and centrifuged at 
2000g for 10 minutes.  Serum was harvested and stored at -20°C until antibody ELISAs were 
performed.  Ninety-six-well microtitre plates (Immunolon 2 HB, Dynex Technologies Inc., 
Chantilly, VA, USA) were coated with whole cell suspensions of the S. aureus Wood 46 strain.  
The Wood-46 strain was used as it lacks the immunoglobulin binding protein, protein A, and has  
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Table 4.1.  Serum antibody titres specific for S. aureus and SEC from beef steers used as blood 
donors.  Animals were used for experiments determining responses to SEC.  Serum titres were 
calculated using a regression model with a positive titre being defined as values exceeding the 
mean plus two standard deviations of the negative control.   
Cow ID S. aureus titre SEC titre 
1 11143 4369 
2 3349 800 
3 10794 3733 
4 794 700 
 
 
Table 4.2.  Serum titres against S. aureus and stimulation indices against staphylococcal alpha 
toxin from dairy cattle used as blood donors.  Animals were used for experiments determining 
responses to S. aureus.  Serum titres were determined as in table 4.1.  Stimulation index was 
calculated by dividing counts obtained with stimulated cells by those obtained with unstimulated 
controls. 
Cow ID S. aureus titre Stimulation index 
552 1214680 397.68 
581 300057 332.67 
609 1082091 368.10 
620 961299 115.54 
656 264882 249.78 
660 602003 149.30 
666 852887 495.79 
667 864319 275.30 
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been demonstrated to specifically bind bovine antibodies against S. aureus in an ELISA [264].  
An overnight culture of the Wood 46 strain was added to trypic soy broth (TSB) (BD 
Biosciences, Mississauga, ON) at a 1:100 dilution and incubated at 37°C with shaking until the 
mid-exponential growth phase.  Bacteria were then centrifuged at 6000g for 10 minutes at 4°C 
then washed once in PBS (0.1M, pH 7.2).  Bacteria were then suspended in PBS to give an 
absorbance of 0.2 at 600nm and 100µl of this suspension was added to each well of the 
microtitre plate.  Plates were incubated overnight at 4°C then washed five times with 200µl Tris-
buffered saline (1M Tris-HCl, 1.8M NaCl, pH 7.5) containing 0.05% Tween-20 (TBS-T).  
Serum samples were added to each well beginning with 100µl of a 1:100 dilution in TBS-T 
containing 0.5% gelatin (TBS-TG).  Serial fourfold dilutions were made such that seven serial 
dilutions were made in TBS-TG.  Plates were incubated at room temperature for one hour then 
washed as before.  Following the wash, 100µl of a mouse anti-bovine IgG (H+L) antibody 
conjugated to alkaline phosphatase (Bethyl Laboratories, Montgomery, TX, USA) was added in 
TBS-TG to each well.  Plates were incubated at room temperature for one hour then washed as 
before.  Following the wash, 100µl of a 1mg/ml p-nitrophenyl phosphate (Sigma-Aldrich, 
Oakville, ON) in substrate buffer (0.1M Diethanolamine, 0.5mM MgCl2, pH 9.8) was added to 
each well.  Plates were incubated at room temperature for 30 minutes and read using a microtitre 
plate reader with absorbance set at 405nm and reference set at 490nm.  Titres were calculated 
using a regression model with a positive titre being defined as the optical density exceeding 
mean plus two standard deviations of the negative control. 
 
Blood samples for proliferation assays were collected into vacutainer tubes containing EDTA as 
an anticoagulant.  Peripheral blood mononuclear cells were isolated and purified according to the 
protocol in section 4.2.1.  Following isolation and purification, 100µl of a 3.5x10
6
 cells/ml 
PBMC suspension in minimum essential media (Invitrogen Canada Inc., Burlington, ON) 
containing 10% fetal bovine serum, 50µM 2-mercaptoethanol, 1% sodium pyruvate, 1% non-
essential amino acids and 1% HEPES (MEM-plus) with 50µg/ml gentamycin was added to each 
well of a 96 well tissue culture plate (Corning Inc., Corning, NY, USA).  Antigens were prepared 
and 100µl of antigen solution in MEM-plus was added to each plate.  Final antigen concentration 
was 0.5µg/ml staphylococcal alpha toxin (Sigma Aldrich, Oakville, ON) or 1µg/ml concanavalin 
A (Sigma) as a positive control.  Plates were incubated at 37°C in 5% CO2 for 72 hours then 
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20µl of a 0.4µCi/ml solution of tritiated thymidine was added to each well.  Plates were 
incubated for a further 18 hours and frozen until harvest.  Following harvest, incorporation of 
tritiated thymidine was determined using a liquid scintillation counter (TopCount NXT, Perkin 
Elmer Inc., Waltham, MA, USA).  Stimulation index was calculated by dividing counts obtained 
with stimulated cells by those obtained with unstimulated controls. 
 
4.1.2 Sheep for in vivo studies 
To establish a model of ovine IMI, nonlactating Suffolk ewes were purchased from the 
University of Saskatchewan Sheep Farm.  Ewes were nonlactating and negative for S. aureus 
based on three sequential negative lacteal secretion cultures.  Following screening, nine ewes 
possessing a total of 14 uninfected udder halves were identified.  Details of which udder halves 
were challenged with which S. aureus isolate are in table 4.3.  Lacteal secretion samples for 
culture and SCC were collected on days 3, 6, 9, 12 and 15 following challenge.  Clinical 
examinations were performed on all animals from days 1-9, 12 and 15 following challenge.  
Specifically, animals were checked for clinical mastitis, systemic disease and rectal temperature.  
Animals were humanely euthanized 15 days following challenge.  Clinical mastitis was defined 
as abnormal milk alongside mammary gland inflammation. 
 
Milk SCCs were determined according to International Dairy Federation Standard 148A:1995 
(Enumeration of Somatic Cells).  Milk samples were mixed with a fixative liquid (0.02% eosin 
in 3.5% formaldehyde solution) at a 50:1 ratio.  Somatic cells were fixed at 30°C for 18 hours 
then cooled to room temperature. Samples were then added to an emulsifier electrolyte mixture 
(12.5% ethanol, 2% TritonX-100 in 0.9% sodium chloride solution) at a 1:100 ratio and heated to 
80°C for 10 minutes.  Samples were cooled to room temperature and somatic cells were counted 
using a Coulter counter (Beckman Coulter, Mississauga, ON). 
 
To determine the effects of S. aureus isolates on ovine mammary immune responses in vivo, 
lactating Suffolk ewes were purchased from the University of Saskatchewan Sheep Farm.  Ewes 
were negative for S. aureus based on three sequential negative milk cultures.  Ewes had high 
antibody responses to S. aureus and high proliferative responses to staphylococcal alpha toxin 
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(table 4.4).  Following screening, twelve ewes possessing a total of 24 uninfected udder halves 
were identified.  All animals were challenged with 50cfu of a S. aureus isolate in 2ml sterile,  
 
Table 4.3.  Animals and udder halves challenged with S. aureus in order to establish a model of 
ovine S. aureus IMI.  Challenge doses were administered in 2ml sterile, endotoxin-free PBS.  
Animal 10-11 possessed an IMI in the left udder half, animals 10-15 and 10-16 possessed an IMI 
in the right udder half therefore these udder halves were not challenged. 
Ewe ID Udder half Challenge isolate Challenge dose (cfu) 
08-60 
L SA8 10 
R SA10 10 
10-10 
L SA8 10 
R SA10 10 
10-11 R SA10 10 
10-12 R SA8 10 
10-13 
L SA8 50 
R SA10 50 
08-225 
L SA8 50 
R SA10 50 
10-14 
L SA8 200 
R SA10 200 
10-15 L SA8 200 
10-16 L SA10 200 
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Table 4.4.  Serum antibody titres against S. aureus and PBMC proliferative responses to 
staphylococcal alpha toxin from ewes.  Ewes were used to determine the effects of S. aureus 
isolates on ovine mammary immune responses in vivo.  Serum antibody titres and stimulation 
indices were determined as in tables 4.1 and 4.2, respectively. 
Ewe ID S. aureus titre Stimulation index 
10-34 312774 290.73 
10-35 77071 48.05 
10-36 72641 163.61 
10-37 254736 291.66 
08-38 301114 111.64 
10-39 240416 98.38 
10-40 203037 66.30 
10-41 239047 145.62 
10-42 109335 44.18 
10-43 296189 26.28 
10-44 227603 89.51 
08-64 257326 25.24 
 
 
endotoxin-free PBS.  Six animals were humanely euthanized on day 3 following challenge to 
characterize acute responses.  The remaining six animals were humanely euthanized on day 15 
following challenge to characterize chronic responses (table 4.5).  Milk samples for culture and 
SCC were collected on days 1, 3, 6, 9, 12 and 15 following challenge.  Clinical examinations 
were performed on all animals as per the above protocol.  Following euthanasia, SMLN samples 
were collected into MEM-plus for FACS analysis.  Samples of SMLN, mammary parenchyma 
and teat ends were collected into a commercial RNA preservative (RNAlater, Ambion Inc., 
40 
 
Austin, TX, USA) for future RNA extraction and qRT-PCR analysis.  Samples of SMLN, 
mammary parenchyma and teat ends were collected into a commercial cryopreservative 
(Shandon Cryomatrix, Fisher Scientific, Nepean, ON) for immunohistochemical assays. 
 
 
Table 4.5.  Animals and udder halves challenged with S. aureus to determine the effects of S. 
aureus isolates on ovine mammary immune responses in vivo. 
Ewe ID Udder half Challenge isolate Day euthanized 
10-34 R SA10 3 
10-35 L SA8 3 
10-36 L SA8 15 
10-37 L SA10 3 
08-38 L SA8 15 
10-39 R SA10 15 
10-40 R SA10 15 
10-41 R SA8 3 
10-42 R SA8 3 
10-43 L SA10 15 
10-44 R SA10 3 
08-64 R SA8 15 
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4.1.3 Preparation of Staphylococcus aureus challenge suspensions 
Challenge suspensions were prepared by inoculating 5ml of sterile tryptic soy broth (TSB) with 
the appropriate S. aureus isolate.  Isolates were taken from the Vaccine and Infectious Disease 
Organization culture collection.  Isolates SA8, SA10, SA12, SA23 and SA45 possessed the sec 
gene.  Cultures were incubated overnight at 37°C with shaking.  The overnight culture was added 
to sterile TSB at a 1:100 concentration and incubated at 37°C with shaking until the optical 
density at 600nm had reached 0.35.  Cultures were centrifuged at 3000 g for 10 minutes at 4°C 
then washed twice with 25ml sterile PBS.  Cultures were then suspended in 10ml sterile PBS and 
serial tenfold dilutions were made.  Bacterial counts were enumerated by plating on TSA and 
incubating at 37°C overnight with 5% CO2.  During this time, the bacteria were stored in PBS at 
4°C.  Based on the bacterial counts, bacteria were diluted in PBS such that the appropriate 
bacterial count in the challenge suspension was obtained.  Bacterial counts in the challenge 
suspension were confirmed by plating on TSA and incubating overnight. 
 
  
4.2 Peripheral blood mononuclear cell assays 
4.2.1 Isolation and purification of peripheral blood mononuclear cells 
Blood samples were collected into vacutainers containing EDTA as an anticoagulant.  
Vacutainers were centrifuged at 1350g for 20 minutes at room temperature.  The buffy coats 
were removed and suspended in 8ml of PBSA containing 2.7mM EDTA (PBSA/EDTA), layered 
over 5ml Ficoll (GE Healthcare, Uppsala, Sweden) and centrifuged at 1940g for 30 minutes at 
room temperature.  Peripheral blood mononuclear cells were removed from the interface 
between PBSA/EDTA and Ficoll, resuspended in 10ml PBSA/EDTA and centrifuged at 311 g 
for 10 minutes at room temperature.  Cells were washed twice more in 10ml PBSA/EDTA then 
resuspended in 4ml MEM-plus.  Cell counts were determined using a Coulter counter and 
resuspended to the concentration required for the assay. 
 
4.2.2 Preparation of Staphylococcus aureus suspensions 
Suspensions of S. aureus were prepared by inoculating 5ml of MEM-plus with the appropriate 
stock S. aureus isolate.  Cultures were incubated overnight at 37°C with shaking.  The overnight 
culture was added to sterile MEM-plus at a 1:100 concentration and incubated at 37°C with 
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shaking until a mid-log growth phase was reached.  The resultant bacterial suspension was 
centrifuged at 3000g for 10 minutes at 4°C then washed twice with 25ml sterile PBS.  Cultures 
were suspended in 10ml sterile PBS and bacterial counts were enumerated using a 
haemocytometer.  Bacterial counts were confirmed by plating serial tenfold dilutions on TSA 
and incubating overnight. 
 
4.2.3 Co-culture of peripheral blood mononuclear cells with Staphylococcus aureus 
Isolated PBMCs were added to tissue culture plates at a concentration of 10
6
 cells/ml.  If the cells 
were to be used for fluorescent activated cell sorting (FACS), 6 well tissue culture plates 
(Corning) were used with a total volume of 4ml/well.  If the cells were to be used for cytokine 
quantification by ELISA or qRT-PCR, 12 well tissue culture plates (Corning) were used with a 
total volume of 1ml/well.  Staphylococcus aureus was added to each well such that the final 
concentration was 10
4
 cfu/ml.  To prevent overgrowth of S. aureus in the culture medium, a final 
concentration of 1µg/ml tetracycline was added to all culture media.  This concentration was 
determined by incubating S. aureus isolates in MEM-plus containing various concentrations of 
tetracycline until a concentration of tetracycline which resulted in the number of viable S. aureus 
in the media to remain constant over 72 hours was identified.  The PBMCs and S. aureus were 
co-cultured for 24, 48 and 72 hours. 
 
 
4.3 Quantitative real-time PCR assays 
4.3.1 Isolation, purification and quantification of RNA 
To isolate RNA from PBMCs, tissue culture plates were centrifuged at 220g for 10 minutes at 
4°C to pellet the cells.  Culture supernatants were removed and 1ml Trizol ® (Invitrogen Canada 
Inc., Burlington, ON) was added to each well.  Plates were stored at -80°C until RNA isolation 
was performed.  Plates were thawed at 56°C for 1 minute and samples were mixed and placed 
into RNase-free microcentrifuge tubes.  Samples were incubated at room temperature for five 
minutes then 200µl chloroform was added to each tube.  Samples were thoroughly mixed and 
incubated at room temperature for two minutes then centrifuged at 12,000g for 15 minutes at 
4°C.  Following centrifugation, the aqueous phase was removed from the sample and transferred 
to a clean RNase-free microcentrifuge tube.  To precipitate the RNA, 500µl isopropanol was 
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added to each sample then samples were mixed by inversion and incubated at room temperature 
for 10 minutes.  Samples were then centrifuged at 12,000g for 10 minutes at 4°C.  Supernatants 
were removed; samples were suspended in 1ml of 75% ethanol and centrifuged at 7,600g for five 
minutes at 4°C.  Supernatants were removed and samples were air dried for 15 minutes at room 
temperature.  Samples were resuspended in 40µl RNase-free water followed by incubation at 
56°C for five minutes, mixed and incubated at 56°C for a further five minutes to fully suspend 
RNA.   
 
To isolate RNA from tissue samples, tissues were collected into RNAlater (Invitrogen) and 
frozen at -20°C until RNA isolation was performed.  Samples were thawed on ice, a 3mm cubic 
section was cut, placed in Trizol ® and homogenized using zirconia beads.  Chloroform (200µl) 
was added to each sample; samples were thoroughly mixed and centrifuged at 12,000g for 15 
minutes at 4°C.  Following centrifugation, 200µl of the aqueous phase was added to a RNase-
free microcentrifuge tube.  This was then added to an RNase cleanup column (RNeasy Mini Kit, 
QIAGEN Inc., Mississauga, ON) which allows for the further isolation and purification of RNA 
from the sample.  Briefly, ethanol was added to the sample to allow binding of RNA to the 
column membrane.  Total RNA was bound to the membrane then the membrane was washed to 
remove contaminants.  The RNA was eluted from the membrane using RNase-free water.  
Extracted RNA was stored at -80°C until reverse transcription.  Concentration of extracted RNA 
was determined by spectrophotometer. 
 
4.3.2 Reverse transcription to make cDNA 
Isolated RNA was thawed at 56°C.  Sample concentration was adjusted such that 500ng RNA in 
10µl RNase free water (Invitrogen) was present in a 200µl RNase free tube and 1µl of a 100U/ml 
DNaseI solution (Invitrogen) was added to each sample.  Samples were incubated for 20 minutes 
at room temperature then 1µl of 25mM EDTA (Invitrogen) was added to each sample and 
samples were incubated at 65°C for 10 minutes to inactivate DNaseI.  Reverse transcription was 
achieved by reverse-transcription PCR using random hexamer primers and superscript II reverse 
transcriptase (Invitrogen).  The PCR reaction was carried out using a thermocycler with samples 
held at 42°C for 20 minutes then 95°C for 10 minutes.  Samples were stored at -20°C until 
quantitative real-time PCR was performed. 
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4.3.3 Quantitative real-time PCR 
Quantitative real-time PCR was performed using SYBR Green (Invitrogen) on a Bio-Rad iCycler 
(Bio-Rad Laboratories, Mississauga, ON) according to the manufacturer’s protocol.  Primers for 
sense and anti-sense strands of the β-actin, IFN-γ, IL-4 and IL-10 genes were designed based on 
published sequences of the gene of interest.  Products from PCR were run on a 1% agarose gel to 
ensure that a single product of the appropriate length was generated.  Products from PCR were 
also sequenced and compared with the reference sequence to ensure that the appropriate gene 
was amplified.  Details of primers are in table 4.6.  The qRT-PCR analysis was performed in 
duplicate using the housekeeping gene β-actin as a reference.  Cytokine gene expression was 
normalized to β-actin and expressed as relative expression by comparison with untreated controls 
using the comparative threshold cycle (ΔΔCt) method. 
 
Table 4.6.  Primers used to amplify cytokine and housekeeping gene mRNA transcripts.  Primer 
sequence and product length are reported 
Gene Primer direction Primer sequence 
Product 
length (bp) 
β-actin 
Forward 5´-AGGCATCCTGACCCTCAAGTA-3´ 
95 
Reverse 5´-GCTCGTTGTAGAAGGTGTGGT-3´ 
Bovine IL-4 
Forward 5´-ACGCTGAACATCCTCACAAC-3´ 
125 
Reverse 5´-CGCCTAAGCTCAATTCCAAC-3´ 
Ovine IFN-γ 
Forward 5´-TCCAGCGCAAAGCCATCAATGAAC-3´ 
105 
Reverse 5´-TCCGGCCTCGAAAGAGATTCTGAC-3´ 
Ovine IL-4 
Forward 5´-ACGCCGAACATCCTCACATC-3´ 
172 
Reverse 5´-CAAGTCCGCCCAGGAATTTG-3´ 
Ovine IL-10 
Forward 5´-GATGCCACAGGCTGAGAACC-3´ 
53 
Reverse 5´-GCGAGTTCACGTGCTCCTTG-3´ 
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4.4 Fluorescence-activated cell sorting assays 
4.4.1 Isolation, purification and quantification of cells 
For assays involving PBMCs, cells were isolated according to the protocol in section 4.1.1 and 
incubated in MEM-plus for the appropriate time.  If the cells were to be used for intracellular 
cytokine staining, a protein transport inhibitor containing monensin (GolgiStop, BD Biosciences) 
was added to each well according to manufacturer’s directions for the final ten hours of 
incubation.  This treatment allows proteins to accumulate in the cells and enhances staining of 
intracellular cytokines.   Following incubation, cells were removed from wells, placed in a 
polypropylene tube and centrifuged for 311g at 4°C.  Cell pellets were washed once with PBSA.  
The pellet was suspended in FACOLA staining media (PBSA supplemented with 1% fetal calf 
serum, 0.09% sodium azide, pH 7.5) such that the cell concentration was 2 x 10
7
 cells/ml. 
 
For assays involving cells isolated from lymph nodes, the distal third of the lymph node was 
collected within 10 minutes of euthanasia and immediately placed in a tube containing ice cold 
culture media and transported on ice for processing.  They were then placed in a Petri dish 
containing culture media and cut into 2-3mm diameter fragments.  Tissue fragments were placed 
in a 40µm cell strainer (BD Biosciences) and filtered into a fresh tube using culture media.  For 
cell surface marker staining, cells were centrifuged at 325g for 8 minutes at 4°C and washed 
once in PBSA.  Cells were resuspended in FACOLA such that the cell concentration was 2 x 10
7
 
cells/ml.  For intracellular cytokine staining, 4ml of a 10
6
 cells/ml suspension was placed into 
wells of a 6 well plate.  Cells were then incubated for 12 hours in the presence of GolgiStop.  
Following incubation, cells were removed from wells, placed in a polypropylene tube and 
centrifuged for 311g at 4°C.  Cell pellets were washed once with PBSA.  The pellet was 
resuspended in FACOLA staining media (PBSA supplemented with 1% fetal calf serum, 0.09% 
sodium azide, pH 7.5) such that the cell concentration was 2 x 10
7
 cells/ml. 
 
 
4.4.2 Fluorescent antibody staining 
Following recovery of cells, 50µl of the 2x10
7
 cells/ml suspension was added to wells of a 96 
well microtiter plate (Corning Inc., Corning, NY, USA) and 50µl of an appropriate murine anti-
bovine lineage specific monoclonal antibody was added.  Details of antibodies used in 
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fluorescent antibody staining are contained in table 4.7.  Isotype controls were used to allow for 
accurate quantification of background binding.  One well was left unstained to allow for 
quantification of cell autofluorescence.  Cells were incubated on ice for 30 minutes in the dark 
then washed by adding 100µl FACOLA to each well, centrifuging at 349g for 2 minutes at 4°C 
then adding 200µl FACOLA and repeating the centrifugation.  The procedure was repeated for a 
total of three washes.  The cell pellets were suspended in 50µl FACOLA and 50µl of an 
appropriate isotype-specific fluorochrome-conjugated secondary antibody was added to each  
well.  Cells were incubated on ice for 30 minutes in the dark then washed as above.  If cell 
surface staining alone was to be performed, cells were fixed by resuspending in 200µl of 2% 
formaldehyde (Sigma) and the plates were stored in the dark at 4°C for a maximum of 7 days 
before analysis. 
 
If intracellular staining was to be performed, cells were resuspended in 100µl of a commercially-
available fixation/permeabilization solution (BD Cytofix/Cytoperm, BD Biosciences) and 
incubated for 20 minutes at 4°C in the dark.  Cells were washed twice in a commercial 
permeabilization washing buffer (BD Perm/Wash Buffer, BD Biosciences).  Centrifugation 
during the wash steps was at 863g for 5 minutes at 4°C.  The increased centrifugal force was 
used as cell buoyancy increases following permeabilization.  Cells were resuspended in 50µl 
buffer containing an appropriate concentration of either a fluorochrome or biotin-conjugated 
anti-cytokine antibody.  Cells were incubated for 30 minutes in the dark at 4°C.  If a 
fluorochrome-conjugated anti-cytokine antibody was used, cells were washed as before and 
resuspended in 200µl FACOLA and the plates were stored in the dark at 4°C for a maximum of 
7 days before analysis.  If a biotin-conjugated anti-cytokine antibody was used, cells were 
resuspended in 50µl buffer containing 0.25µg/ml strepavidin conjugated to fluorescin 
isothiocyanate (FITC) (Serotec, Raleigh, NC, USA).  Cells were incubated for 30 minutes in the 
dark at 4°C, washed as before, resuspended in 200µl FACOLA and stored as for the other assays. 
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Table 4.7.  Antibodies used in fluorescent antibody staining of cells for flow cytometric analysis.   
Antibody Isotype Supplier and clone 
Working dilution 
(µg/ml) 
Mouse anti-bovine CD4 IgG2a VMRD IL-A11 10 
Mouse anti-bovine CD8 IgM VMRD BAQ111A 6.7 
Mouse anti-bovine TcR-N24 
(γδ T lymphocytes) 
IgG2b VMRD GB21A 2.5 
Mouse anti-ovine CD4 IgM VMRD GC50A1 10 
Mouse anti-ovine CD8 IgG1 VMRD CACT80C 10 
Mouse anti-ovine TcR-N6 
(γδ T lymphocytes) 
IgM VMRD CACTB6A 10 
Mouse anti-ovine CD11c IgM VMRD BAQ153A 10 
Mouse anti-bovine IFN-γ 
FITC 
IgG1 
Serotec 
MCA1783F 
10 
Mouse anti-bovine IL4 Biotin IgG2b 
Serotec 
MCA2372B 
5 
Mouse anti-bovine IL10 
Biotin 
IgG1 
Serotec 
MCA2111B 
20 
Goat anti-mouse IgM PE  Invitrogen M31504 5 
Goat anti-mouse IgG1 PE  Invitrogen M32017 5 
Goat anti-mouse IgG2a PE  Invitrogen M32204 5 
Goat anti-mouse IgG2b PE  Invitrogen M32404 2.5 
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4.4.3 Flow cytometry 
The purposes of the flow cytometry experiments were to determine changes in cell surface 
marker expression on PBMC and lymph node cells and to determine the cellular source of 
cytokine production.  Variables in the experiment were the proportion of cells staining for each 
cell surface marker or cytokine. 
 
Specimens were taken from bovine PBMCs cultured in the presence of staphylococcal 
enterotoxin C, co-cultures of bovine PBMCs and S. aureus, freshly isolated cells from ovine 
supramammary lymph nodes (SMLNs) or from co-cultures of SMLN cells and S. aureus.  Cell 
surface markers and cytokines were detected by staining with the appropriate primary and 
secondary antibodies as detailed in section 4.4.2.  Secondary antibodies were conjugated to either 
the phycoerythrin (PE) or fluorescein isothiocyanate (FITC) fluorophores.  These were detected 
by stimulation with a laser of an appropriate frequency using a FACScan flow cytometer (BD 
Biosciences).  Data were analyzed with the CellQuest program (BD Biosciences).  Cells were 
characterized according to cell size (forward scatter), cell granularity (side scatter) and 
fluorescent staining.  Thresholds for fluorescent staining were determined by using appropriate 
isotype control antibodies.  The number of cells staining for each marker was determined by 
multiplying the proportion of cells stained by the proportion of viable cells following culture. 
 
Compensation was achieved by using known positive cells stained for each fluorophore.  Cells 
stained singly for each fluorophore and cells stained for both were compared and compensation 
was adjusted such that minimal interference between the two fluorophores occurred.  If live cells 
were used in experiments, gating was based on propidium iodide staining to differentiate live 
from dead cells.  If fixed cells were used in experiments, gating was based on previous 
propidium iodide results alongside the forward and side scatter characteristics of the cells.  This 
allows gating of the cells of interest.  For staining of cell surface markers, 10,000 gated events 
were collected.  For intracellular staining of cytokines, 50,000 gated events were collected due to 
the low proportions of cells staining positive for each cytokine. 
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4.5 Enzyme-linked immunosorbent assays 
Detection of IFN-γ, IL-10 and TNF-α into cell culture supernatants was achieved by ELISA.  For 
all procedures, 96 well plates were coated with an anti-bovine cytokine monoclonal antibody 
diluted in carbonate coating buffer (pH 9.6).  Details of antibodies used in the ELISAs are 
contained in table 4.8.   
 
Plates used for each assay were as follows:  IFN-γ and TNF-α: Immunolon 2 (Fisher); IL-10:  
Maxisorp (Fisher).   Diluted antibody was added to plates at a volume of 100μl per well.  Plates 
were incubated overnight at 4°C.  Following incubation, plates were washed four times in TBS-
T.  Samples were applied to plates at 100μl per well at the following dilutions: undiluted, 1:5 and 
1:25.  Dilutions were carried out in TBS-TG.  Standard recombinant bovine cytokines were 
diluted to 1ng/ml (IFN-γ), 150 units/ml (IL-10) or 5ng/ml (TNF-α) in TBS-TG and two-fold 
dilutions were made to form a standard curve.  Plates were incubated for two hours at room 
temperature.  Following incubation, plates were washed four times in TBS-T and an appropriate 
secondary antibody was added at 100µl per well.  Plates were incubated for one hour at room 
temperature then washed four times in TBS-T.  If the secondary antibody was not biotinylated, a 
biotinylated goat anti-rabbit IgG (Invitrogen) was added at a 1:10,000 dilution in TBS-TG at 
100µl per well.  Plates were incubated for one hour at room temperature then washed four times 
in TBST.  Streptavidin alkaline phosphatase (Cedarlane Laboratories, Burlington, ON) was 
added at a 1:5,000 dilution in TBST-G at 100µl per well.  Plates were incubated for one hour at 
room temperature then washed four times in TBST.  Following the wash, 100µl of a 1mg/ml p-
nitrophenyl phosphate in substrate buffer was added to each well.  Plates were incubated at room 
temperature for 30 minutes and read using a microtitre plate reader with absorbance set at 405nm 
and reference set at 490nm.  Reactions were not stopped before reading.  Cytokine 
concentrations were calculated using a regression model which compared the sample absorbance 
with the standard curve. 
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Table 4.8.  Antibodies used in ELISA assays for the detection of cytokines in cell culture 
supernatants. 
Antibody Supplier Clone Working dilution (µg/ml) 
Mouse anti-bovine IFN-γ VIDO 2-2-1A 0.125 
Rabbit anti-bovine IFN-γ VIDO 92-131 0.4 
Mouse anti-bovine TNF-α VIDO 1D11-13 1 
Rabbit anti-bovine TNF-α VIDO Pool 88 0.67 
Mouse anti-bovine IL-10 Serotec CC318 0.5 
Mouse anti-bovine IL-10 biotin Serotec CC320 0.125 
 
4.6 Immunohistochemistry assays 
Tissues for immunohistochemistry (IHC) were harvested immediately following humane 
euthanasia of animals, placed in a commercial fixative (Shandon Cryomatrix), frozen on dry ice 
and stored at -80°C until cutting.  Sections of tissue with a thickness of 6µm were cut on a 
microtome at -20°C, placed on electrostatically charged microscope slides (Superfrost Plus, 
VWR International, Mississauga, ON) and immediately fixed with 100% acetone for 8 minutes.  
Slides were air dried and stored at 4°C for up to two weeks.  For staining, slides were dried at 
room temperature for 20 minutes and washed 3 times with PBSA.  Non-specific protein binding 
was blocked by incubating for 20 minutes in PBSA with 1% goat serum.  Slides were washed 
once in PBSA and non-specific avidin and biotin binding were blocked by adding a commercial 
avidin D blocking solution (Vector Laboratories, Burlington, ON), incubating for 15 minutes, 
washing once with PBSA and then adding a commercial biotin blocking solution (Vector) and 
incubating for a further 15 minutes.  Slides were washed three times in PBSA and incubated for 
60 minutes with 100µl of an appropriate murine anti-bovine lineage specific monoclonal 
antibody.  Slides were washed three times in PBSA and incubated for 60 minutes with 100µl of 
an appropriate biotinylated secondary antibody.  Primary and secondary antibodies used and 
working concentrations are summarized in table 4.9.  Slides were washed three times in PBSA 
and endogenous peroxidase production was blocked by incubating with PBSA containing 0.1% 
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sodium azide and 0.3% hydrogen peroxide for 7 minutes.  Slides were washed twice in PBSA 
and incubated in a commercial avidin-biotinylated peroxidase solution (ABC kit, Vector) for 30 
minutes.  Slides were washed three times in PBSA and a commercial diaminobenzidine 
peroxidase substrate solution (DAB peroxidase substrate kit, Vector) was added for 5 minutes.  
Slides were washed twice in PBSA and fixed for 10 minutes with absolute methanol.  Staining 
was intensified by incubating for 10 minutes in 0.5M copper sulphate.  Slides were washed once 
in distilled water and counterstained for 120 seconds with 5% Giemsa stain in distilled water 
(Sigma).  Slides were washed twice in distilled water, dried overnight and coverslipped using a 
commercial, toluene-based mounting medium (Shurmount, Triangle Biomedical Sciences, 
Durham, NC, USA). 
 
 
 
Table 4.9.  Antibodies used in immunohistochemical assays for the detection of cell surface 
markers. 
Antibody Isotype Supplier and clone Working dilution (µg/ml) 
Mouse anti-ovine CD4 IgM VMRD GC50A1 10 
Mouse anti-ovine CD8 IgG1 VMRD CACT80C 10 
Mouse anti-ovine TcR-N6 
(γδ T lymphocytes) 
IgM VMRD CACTB6A 10 
Mouse anti-ovine CD11c IgM VMRD BAQ153A 10 
Mouse anti-ovine CD205 IgG2b Serotec CC98 10 
Goat anti-mouse IgM biotin  Invitrogen M31515 20 
Goat anti-mouse IgG1 biotin  Invitrogen A10519 20 
Goat anti-mouse IgG2b 
biotin 
 Invitrogen M32515 20 
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4.7 Bacterial DNA manipulations 
4.7.1 Genomic and plasmid DNA extraction 
To extract genomic DNA from S. aureus isolates, bacteria were grown overnight in TSB at 
37°C.  Bacteria were centrifuged at 1940 g for 10 minutes, supernatants were removed and 
bacteria were suspended in 2ml lysis buffer (20mM Tris HCl, 2mM EDTA, 1% Triton-X, 
100µg/ml lysozyme, 5 units/ml lysostaphin and 0.1mg/ml RNaseI).  Bacterial suspensions were 
incubated at 37°C for 30 minutes, bacterial lysis was confirmed visually by observing the 
presence of gelatinous material and 25µl of a 25mg/ml proteinase K solution was added to each 
suspension.  Suspensions were incubated at 56°C for 60 minutes.  Following incubation, 20µl 
sodium acetate (3M, pH 5.2) and 5ml ethanol (100%, -20°C) was added to each isolate to 
precipitate DNA.  Precipitated DNA was removed on a glass spool, rinsed three times in 70% 
ethanol and dissolved overnight in distilled water at 4°C. 
 
To extract plasmid DNA from E. coli isolates, one of two procedures was performed.  If small 
quantities of plasmid DNA were required, bacteria were grown overnight in LB broth at 37°C.  
Aliquots of the bacterial suspensions (1.5ml) were centrifuged at 20,000g for 3 minutes, 
supernatants were removed and bacteria were suspended in 100µl of cold solution I (50mM 
glucose, 25mM TrisHCl, 10mM EDTA) and incubated on ice for 5 minutes.  Following 
incubation, 200µl solution II (0.2N NaOH, 0.5% SDS) was added to each suspension and 
incubated on ice for 5 minutes.  Following incubation, 150µl potassium acetate (3M, pH 5.3) was 
added to each suspension and incubated at -20°C for 10 minutes.  Suspensions were centrifuged 
at 20,000g for 15 minutes, 400µl of the supernatant was transferred to a clean microcentrifuge 
tube and 240µl isopropanol (100%, -20°C) was added to each sample.  Samples were incubated 
for 15 minutes at room temperature then centrifuged at 20,000g for 15 minutes.  Supernatants 
were removed; samples were washed three times in 500µl 70% ethanol and dried at 42°C.  Once 
dry, DNA was resuspended in 50µl RNase (5µg/ml) and incubated for 15 minutes at 37°C.   
 
If plasmid DNA of high purity was required for transformation of bacterial species, a 
commercial DNA purification column was used according to the manufacturer’s instructions 
(QIAGEN Plasmid Midi Kit, QIAGEN Inc.). 
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4.7.2 PCR procedures 
To amplify the sec gene for expression of SEC protein, a S. aureus strain possessing the sec gene 
was obtained.  The presence of the sec gene encoding SEC was demonstrated using PCR primers 
based on published sequences of the gene and designed to amplify the segment of the gene 
encoding the mature protein (table 4.10).  To amplify the sec gene for transforming S. aureus, 
primers were designed to include the promoter sequence for sec (table 4.10).  The template DNA 
was added to a reaction mixture containing a commercial reaction buffer (GE Healthcare), 3mM 
dNTPs, 1.6µM of each primer and 0.1 units of Taq DNA polymerase (Illustra rTaq DNA 
polymerase, GE Healthcare).  Conditions for the PCR reaction were as follows: 1 cycle of 2 
minutes at 94°C; 30 cycles of 1 minute at 94°C, 1 minute at 47°C, 1 minute at 72°C and a final 
cycle of 5 minutes at 72°C.  Aliquots of the sample were analysed by running on a 1% agarose 
gel, resolving the bands by electrophoresis, staining the gel with ethidium bromide and 
photographing the gel under UV light conditions. 
 
Table 4.10.  Primers used for the amplification of DNA sequence to be used in cloning 
experiments. 
Gene  Direction Primer sequence 
SEC 
Forward 5´-AAAAAGGATCCGAGAGCCAACCAGACCCTACG-3´ 
Reverse 5´-AAAAACCCGGGTTATCCATTCTTTGTTGTAAGG-3´ 
SEC with 
promoter 
sequence 
Forward 5´-AAAAAGAATTCTTGAATATTTAAGATTATAAGATATATTTAAAG-3´ 
Reverse 5´-AAAAACCCGGGTTATCCATTCTTTGTTGTAAGG-3´ 
 
 
4.7.3 Restriction digestion and DNA ligation procedures 
For expression of the SEC protein, the PCR product and pQE-30 expression vector were digested 
with the BamHI and SmaI restriction enzymes according to the manufacturer’s instructions (New 
England BioLabs (NEB), Pickering, ON).  The sec gene was ligated into the pQE-30 expression 
vector using a commercial DNA ligase enzyme according to the manufacturer’s instructions 
(NEB).  The gene was sequenced and BLAST analysis of the gene sequence revealed a 92% 
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homology with the published sequence. BLAST analysis of the protein sequence revealed a 
100% homology with the published sequence. 
 
For transformation of S. aureus with sec, the PCR product and pAW11 shuttle vector were 
digested with the EcoRI and SmaI restriction enzymes according to the manufacturer’s 
instructions (NEB).  The sec gene was ligated into the pAW11 vector using a commercial DNA 
ligase enzyme according to the manufacturer’s instructions (T4 DNA ligase, NEB). 
 
4.7.4 Transformation of Escherichia coli and Staphylococcus aureus strains with DNA 
Electrotransformation was used to transform bacterial strains with DNA.  Escherichia coli cells 
for use in electrotransformation procedures were prepared according to the following procedure.  
Fresh LB broth was inoculated with a 1/100 volume of a fresh overnight E. coli culture.  Bacteria 
were grown at 37°C with shaking until the optical density at a wavelength of 600nm was 0.3-0.4.  
Cells were chilled on ice for 15 to 30 minutes then centrifuged at 4,000g for 15 minutes at 4°C.  
Supernatants were removed and cell pellets were resuspended in an identical volume of cold 
water.  Cells were centrifuged as before and resuspended in 50% of the volume of cold water.  
Cells were centrifuged as before and resuspended in 4% of the original volume of 10% glycerol.  
Cells were centrifuged a final time and resuspended in 10% glycerol such that the final cell 
concentration was 3 x 10
10
 cells/ml.  Cells were frozen in 50µl aliquots on dry ice and stored at -
70°C.  Staphylococcus aureus cells for use in electrotransformation procedures were prepared 
according to a similar procedure except cells were cultured in TS broth and washes and 
resuspensions were performed in 500mM sucrose. 
 
Electroporation was performed by adding between 1µg and 5µg DNA to an aliquot of 
electrocompetent bacterial cells.  If E. coli was to be transformed, the mixture was added to a 
1mm or 2mm electroporation cuvette.  For 1mm cuvettes, electroporation was carried out at 
1.8kV with a 25µF capacitor and the pulse controller unit set to 200Ω.  For 2mm cuvettes, the 
electroporation was carried out at 2.5kV with no change to the other parameters.  If S. aureus 
was to be transformed, the mixture was added to a 2mm electroporation cuvette and 
electroporation was carried out at 2.5kV with a 25µF capacitor and the pulse controller unit set to 
100Ω.  Immediately following electroporation, transformed E. coli were placed in SOC media 
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(2% bacto-tryptone, 0.5% w/v bacto-yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 
20mM glucose) for 1 hour at 37°C for non-temperature sensitive plasmids or 2 hours at 30°C for 
temperature sensitive plasmids.  Transformed S. aureus were placed in TS broth for 4 hours at 
37°C for non-temperature sensitive plasmids or 6 hours at 30°C for temperature sensitive 
plasmids.  Following recovery, bacteria were plated on either LB agar (E. coli) or TS agar (S. 
aureus) containing an appropriate antibiotic concentration for the plasmid used.  Details of 
antibiotic concentrations for each plasmid are included in table 4.11. 
 
Table 4.11 Antibiotic concentrations used for each plasmid during cloning experiments 
Plasmid Bacterial species Antibiotic Concentration (µg/ml)  
pQE-30 E. coli Carbenicillin 50  
pAW11 E. coli Erythromycin 300  
pAW11 S. aureus Erythromycin 5  
 
 
 4.7.5 Protein expression, purification and quantification 
To express SEC protein, an overnight culture E. coli transformed with pQE-30 expressing the sec 
gene was added at a 1:100 dilution to LB broth (Difco) and incubated at 30°C with shaking until 
mid-log phase.  Following incubation, 0.2mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to initiate transcription of the lac operon thus inducting protein expression.  Cultures 
were incubated for 2 hours at 37°C with shaking then centrifuged at 3000g for 10 minutes.  
Supernatants were discarded and pellets were suspended in 0.9% sodium chloride and frozen 
overnight.  Cell pellets were thawed on ice and resuspended in lysis buffer (50mM sodium 
phosphate, 300mM sodium chloride, 10mM imidazole, pH 8) and 1mg/ml lysozyme was added.  
The mixture was sonicated (40% amplitude, 10s burst, 10s cooling for 10 cycles on ice) then the 
lysate was centrifuged at 11,500g for 30 minutes at 4°C.  The supernatant was saved for protein 
purification. 
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Use of the pQE-30 plasmid for cloning of the sec gene causes a 6x histidine tag to be present at 
the N-terminus of the SEC protein.  This allows for protein purification using nickel 
chromatography.  The supernatant was added to nickel-NTA resin and mixed at 4°C for 60 
minutes.  The mixture was added to a column, washed three times in wash buffer (50mM sodium 
phosphate, 300mM sodium chloride, 20mM imidazole, pH 8) then protein was eluted with three 
washes in elution buffer (50mM sodium phosphate, 300mM sodium chloride, 250mM imidazole, 
pH 8).  Protein concentration was determined using a modified Lowry technique.  Protein purity 
was determined by running on a 12% SDS-PAGE gel and densitometry. 
 
4.8 Statistical analysis 
To compare the effects of different S. aureus isolates on PBMC cytokine secretion in vitro, a one 
way repeated measures analysis of variance (ANOVA) was performed with isolate as the 
independent variable and time as the repeated measure.  Cytokine secretion data in the current 
studies was not parametrically distributed therefore data were ranked for analysis in accordance 
with previous studies [265-268].  To compare the effects of different isolates on cytokine gene 
expression by PBMCs in vivo, a one way repeated measures ANOVA was performed with 
isolate as the independent variable and time as the repeated measure.  Previous work has 
identified data from similar experiments as being non-parametrically distributed [269-271].  An 
attempt was made to make a logarithmic transformation of the data [271] but this was 
unsuccessful therefore data were ranked for analysis [269, 270]. 
 
To compare bacterial shedding with different S. aureus isolates, a one way ANOVA was 
performed with isolate as the independent variable and time as the repeated measure.  To 
determine the effects of different S. aureus isolates on milk somatic cell counts, a two way 
repeated measures ANOVA was performed with isolate and quarter challenge status as the 
independent variables and time as the repeated measure.  The data from control udder halves 
were subtracted from the data from challenged udder halves to correct for pairing.  Somatic cell 
count data were transformed using a log10 transformation before analysis [4, 6, 213]. 
 
To compare the effects of different S. aureus isolates on leukocyte lineage specific marker and 
intracellular cytokine staining, multiple t-tests were used to compare infected and uninfected 
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udder halves.  To compare the effect of different S. aureus isolates and duration of infection, the 
data from control udder halves were subtracted from the data from challenged udder halves to 
correct for pairing.  These data were then analysed using a two-way ANOVA in which isolate 
and duration of infection were set as the independent variables.  Given that previous work has 
reported that qRT-PCR data regarding cytokine expression in the mammary gland is 
parametrically distributed [206-211], these data were not transformed. 
 
To compare the effects of different S. aureus isolates on cytokine expression in tissues, multiple 
t-tests were used to compare infected and uninfected udder halves.  To compare the effect of 
different S. aureus isolates and duration of infection, the data from control udder halves were 
subtracted from the data from challenged udder halves to correct for pairing.  These data were 
then analysed using a two-way ANOVA in which isolate and duration of infection were set as 
the independent variables.  Given that previous work has reported that qRT-PCR data regarding 
cytokine expression in the mammary gland is parametrically distributed [6, 213], these data were 
not transformed. 
 
All analyses were performed using commercially available statistical analysis software 
(GraphPad Prism, GraphPad Software Inc., La Jolla, CA, USA).  Significance level was set at 
P<0.05.  However, given the low numbers of animals present in each treatment group for in vivo 
studies, differences with P<0.10 may also be truly significant.  Use of increased numbers of 
animals would be able to establish whether differences are truly significant. 
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5.  RESULTS 
5.1 In vitro effects of Staphylococcus aureus isolates on bovine peripheral blood 
mononuclear cells  
5.1.1   Screening of Staphylococcus aureus isolates 
Eight dairy cows with recall responses to S. aureus were sourced from the University of 
Saskatchewan dairy facility and used as blood donors for PBMC isolation.  Nine wild type S. 
aureus isolates were incubated with PBMCs for 24, 48 and 72 hours.  Secretion of IFN-γ (Table 
5.1), IL-10 (Table 5.2) and TNF-α (Table 5.3) into cell culture supernatants was determined by 
ELISA.  Due to the consumption of IL-4 by PBMCs in cell culture [272], IL-4 was assayed by 
determining gene expression using qRT-PCR (Table 5.4). 
 
Table 5.1.  Summary of the effect of different S. aureus isolates on IFN-γ secretion by bovine 
PBMCs.  Median IFN-γ concentrations (pg/ml) are reported.  * represents a significant increase in 
concentration when compared with media alone. 
 
Time (h) 
Isolate 24 48 72 
SA8 5175* 16724* 10592* 
SA10 2178* 2776* 2579* 
SA12 502 871 657 
SA23 1817* 15518* 18645* 
SA25 273 923 710 
SA31 718* 943* 1020* 
SA34 671* 1208* 1165* 
SA37 637 926* 929 
SA45 952* 1342* 3861* 
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Table 5.2.  Summary of the effect of different S. aureus isolates on IL-10 secretion by bovine 
PBMCs.  Median IL-10 concentrations (units/ml) are reported.  * represents a significant increase 
in concentration when compared with media alone. 
 
 
Time (h) 
Isolate 24 48 72 
SA8 358* 394* 428* 
SA10 594* 524* 489* 
SA12 280 226 247 
SA23 59* 103* 195* 
SA25 60* 61* 87 
SA31 164 233 182 
SA34 236* 268* 259* 
SA37 210* 225* 242* 
SA45 196* 163 231* 
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Table 5.3.  Summary of the effect of different S. aureus isolates on TNF-α secretion by bovine 
PBMCs.  Median TNF-α concentrations (pg/ml) are reported.  * represents a significant increase 
in concentration when compared with media alone.  
 
 
Time (h) 
Strain 24 48 72 
SA8 4418* 4471* 3983* 
SA10 7545* 6120* 4490* 
SA12 709 591 694 
SA23 605* 1792* 3264* 
SA25 282 649 1096 
SA31 1172 1249 963 
SA34 1598* 1709* 1599* 
SA37 189 150 277 
SA45 243 1244* 603* 
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Table 5.4.  Summary of the effect of different S. aureus isolates on IL-4 mRNA transcription by 
bovine PBMCs.   Median relative expression values are reported.  * represents a significant 
change in relative expression when compared with media alone. 
 
 
Time (h) 
Strain 24 48 72 
SA8 22.5 0.12 26.5 
SA10 0.40 3.78 0.64 
SA12 0.33 0.06 8.8 
SA23 3.8 0.65 1.12 
SA25 0.60 0.22* 1.04 
SA31 0.99 0.36 1.36 
SA34 2.82 0.61 0.83 
SA37 0.59* 0.20* 3.74* 
SA45 0.33* 0.21* 1.24 
 
 
Six isolates (SA8, SA10, SA23, SA31, SA34 and SA45) significantly increased IFN-γ secretion 
at all time points with one isolate (SA37) significantly increasing IFN-γ secretion following 48 
hours of incubation.  Two isolates (SA8 and SA23) caused dramatic increases in IFN-γ secretion 
compared to other S. aureus isolates.  Two isolates (SA10 and SA45) caused more moderate 
increases in secretion compared to other isolates.  Five isolates (SA8, SA10, SA23, SA34 and 
SA37) significantly increased IL-10 secretion at all time points with one isolate significantly 
increasing IL-10 secretion following 24 and 72 hours of incubation (SA45).  Two isolates (SA8 
and SA10) caused dramatic increases in IL-10 secretion compared to other S. aureus isolates.  
Four isolates (SA8, SA10, SA23 and SA34) significantly increased TNF-α secretion at all time 
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points with one isolate (SA45) significantly increasing TNF-α secretion following 48 and 72 
hours of incubation.  Three isolates (SA8, SA10 and SA23) dramatically increased TNF-α 
secretion compared to other S. aureus isolates.  Transcription of IL-4 mRNA was not 
consistently affected by S. aureus.  Generally, a decrease in transcription was observed.  Two 
isolates (SA37 and SA45) decreased IL-4 transcription at 24 and 48 hours of incubation and one 
isolate (SA25) decreased IL-4 transcription at 48 hours.  One isolate (SA37) increased 
transcription at 72 hours of incubation. 
 
Based on these data, isolate variation appears to exist in the cytokine response of bovine PBMCs 
to S. aureus.  Interestingly, the most dramatic responses appear to be because of isolates which 
possess the sec gene.  However, isolates that possess the sec gene had varying effects.  For 
example, the SA8 and SA23 isolates caused dramatic increases in TNF-α, IFN-γ and IL-10.  This 
suggests that these isolates induce both pro-inflammatory (indicated by IFN-γ and TNF-α) and 
anti-inflammatory (indicated by IL-10 responses).  The SA10 isolate induced a moderate 
increase in IFN-γ but dramatic increases in IL-10 and TNF-α. This suggests that this isolate 
induces both pro-inflammatory and anti-inflammatory response.  Whilst these isolates possess 
the sec gene, the role of sec in these responses is unclear.  As S. aureus RN4220 expressing SEC 
had a minimal effect, it appears that SEC does not have major effects alone. 
  
One major weakness in these data is that, due to the number of cells required for each assay, it 
was impossible to assay all isolates at the same time therefore different isolates were assayed on 
different days.  The experimental model for screening did not allow for variations in PBMC 
responses based on the day the experiment was run.  Therefore, it was decided to re-run the 
isolates that had the largest effects on PBMC cytokine production against a consistent control 
strain of S. aureus.  The RN4220 strain was chosen as the control strain. 
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5.1.2   Comparison of select Staphylococcus aureus isolates with a control strain 
The SA8, SA10 and SA23 isolates were compared against RN4220 due to the large effects that 
they had on PBMC cytokine secretion.  The SA34 isolate was used as it appeared to be 
representative of the remaining screened isolates.  Responses to the RN4220 isolate were 
consistent among assays therefore representative data for RN4220 are presented.  Concentrations 
of IFN-γ were significantly increased by S. aureus SA8 at all timepoints when compared with 
media alone or RN4220.  Concentrations of IFN-γ were significantly increased by S. aureus 
SA10 at all timepoints when compared with media alone and at 24 hours when compared with 
RN4220.  Concentrations of IFN-γ were significantly increased by S. aureus SA23 at 48 and 72 
hours when compared with media alone or RN4220.  Concentrations of IFN-γ were significantly 
increased by S. aureus SA34 at all timepoints when compared with media alone (Figure 5.1).  
The SA8, SA10 and SA23 isolates dramatically increased IFN-γ concentrations compared with 
RN4220.   
 
Figure 5.1.  Effect of S. aureus on IFN-γ secretion by bovine PBMCs at 24, 48 and 72 hours 
incubation when compared with RN4220.  Bars represent median values.  All isolates significantly 
increased IFN-γ secretion compared with media.  No isolate differed significantly with RN4220.  
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Concentrations of IL-10 were significantly increased by S. aureus SA8 at 48 and 72 hours when 
compared with media alone and at 72 hours when compared with RN4220.  Concentrations of 
IL-10 were significantly increased by S. aureus SA10 at all timepoints when compared with 
media alone.  Concentrations of IL-10 were significantly increased by S. aureus SA23 at 48 and 
72 hours when compared with media alone and at 24 hours when compared with RN4220. 
Concentrations of IL-10 were significantly increased by S. aureus SA34 at 48 and 72 hours when 
compared with media alone and at 24 hours when compared with RN4220 (Figure 5.2).  
Interestingly, the IL-10 concentrations generated by the SA10 isolate appeared smaller than 
those generated when this isolate was run previously.  Given that no positive control was run 
previously, I believe the SA10 data reported here to be representative of the normal behaviour of 
SA10. 
 
Figure 5.2.  Effect of S. aureus on IL-10 secretion by bovine PBMCs at 24, 48 and 72 hours of 
incubation compared with RN4220.  Bars represent median values.  All isolates significantly 
increased IL-10 secretion compared with media.  No isolate differed significantly with RN4220.  
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Concentrations of TNF-α were significantly increased by S. aureus SA8 at all timepoints when 
compared with media alone or RN4220.  Concentrations of TNF-α were significantly increased 
by S. aureus SA10 at all timepoints when compared with media alone.  Concentrations of TNF-α 
were significantly increased by S. aureus SA23 at 48 and 72 hours when compared with media 
alone or RN4220.  Concentrations of TNF-α were significantly increased by S. aureus SA34 at 
all timepoints when compared with media alone (Figure 5.3).  The SA10 and SA23 isolates 
dramatically increased TNF-α concentrations compared with RN4220.  Expression of IL-4 was 
significantly increased compared with media alone by SA8 at 48 hours, by SA10 at 24 and 48 
hours and by SA23 and 48 and 72 hours.  Expression was significantly increased compared with 
RN4220 by SA8 at 24 and 48 hours, by SA10 at 24 hours and by SA23 at 24, 48 and 72 hours 
(Figure 5.4).  Expression of IL-4 was unaffected by the SA34 isolate. 
 
Figure 5.3.  Effect of S. aureus on TNF-α secretion by bovine PBMCs at 24, 48 and 72 hours of 
incubation compared with RN4220.  Bars represent median values.  All isolates significantly 
increased TNF-α secretion compared with media.  No isolate differed significantly with RN4220.  
M
e
d
ia
S
A
8
S
A
1
0
S
A
2
3
S
A
3
4
R
N
4
2
2
0
M
e
d
ia
S
A
8
S
A
1
0
S
A
2
3
S
A
3
4
R
N
4
2
2
0
M
e
d
ia
S
A
8
S
A
1
0
S
A
2
3
S
A
3
4
R
N
4
2
2
0
0
5000
10000
13000
20000
24h 48h 72h
[T
N
F
- 
] 
p
g
/m
l
 
 
 
 
66 
 
Figure 5.4.  Effect of S. aureus on IL-4 expression by bovine PBMCs at 24, 48 and 72 hours of 
incubation compared with RN4220.  Bars represent median values.  * indicates significantly 
increased IL-4 expression compared with RN4220.  
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It is important to identify the cellular source of IL-10 since it may indicate the presence of 
regulatory T cells.  Intracellular staining for IL-10 was carried out on PBMCs exposed to the 
SA8 isolate.  Observation of the flow cytometry profiles suggested that a population of CD4+ 
IL10+ cells was generated by the SA8 isolate which was not generated by RN4220 (Figure 5.5).  
Analysis of the number of viable cells of each type revealed that SA8 generated significantly 
higher numbers of CD4+ IL10+ cells than either RN4220 or media alone (Figure 5.6).  The 
source of IL-10 in cells exposed to RN4220 appears to be CD8 and γδ T cells (Figures 5.5 and 
5.6). 
 
Based on these data, the isolate variation observed in the cytokine response of bovine PBMCs to 
S. aureus is consistent with what was reported in section 5.1.1.  These data are stronger however 
as assays were run with a consistent positive control.  Generally, S. aureus isolates appear to 
cause increases in IFN-γ, IL-10 and TNF-α secretion and IL-4 expression compared with media 
alone although differences between isolates are apparent.   
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Figure 5.5.  Representative flow cytometry profiles from cells co-cultured with PBMCs and S. 
aureus.  Panel (a) indicates the gated cell population, panel (b) represents CD4+ IL-10+ cells 
incubated with media alone, panel (c) represents CD4+ IL-10+ cells incubated with SA8 and panel 
(d) represents CD4+ IL-10+ cells incubated with RN4220. 
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Figure 5.6.  Cellular source of IL-10 following incubation of SA8 with bovine PBMCs for 24 
hours.  Number of viable cells was determined as in section 4.4.3.  Bars represent median values.  
* denotes a significant increase in viable cell numbers compared with RN4220.  Panel (a) 
represents CD4+ IL-10+ cells, panel (b) represents CD8+ IL-10+ cells and panel (c) represents γδ+ 
IL-10+ cells. 
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5.2 Effects of staphylococcal enterotoxin C on bovine peripheral blood mononuclear cells in 
vitro 
5.2.1 Effect of purified staphylococcal enterotoxin C protein on bovine peripheral blood 
mononuclear cells 
To determine the effect of SEC protein on bovine PBMCs, mixed breed naive beef calves were 
used as blood donors.  Cells were incubated with 10µg/ml SEC protein for 24, 48 and 72 hours.  
Secretion of IFN-γ and IL-10 into culture supernatants was determined by ELISA and expression 
of cell surface markers (CD4, CD8, CD25, ACT2) was determined by flow cytometry.  
Incubation with SEC did not significantly affect concentrations of IFN-γ in cell culture 
supernatants (Figure 5.7) but did increase IL-10 concentrations at 48 and 72 hours (P = 0.020) 
(Figure 5.8).  Cell surface marker expression did not vary with exposure to SEC protein (Figures 
5.9 and 5.10). 
 
Figure 5.7.  Concentration of IFN-γ in culture supernatants following incubation of bovine 
PBMCs in the presence or absence of 10μg/ml SEC for 24, 48 or 72 hours.  Bars represent 
median values. 
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Figure 5.8.  Concentration of IL-10 in culture supernatants following incubation of bovine 
PBMCs in the presence or absence of 10μg/ml SEC for 24, 48 or 72 hours.  Bars represent 
median values.  * represents a significant (P < 0.05) increase in IL-10 compared with media 
alone. 
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Figure 5.9.  Representative flow cytometry profiles from PBMCs co-cultured with media alone 
(panel a) or 10μg/ml staphylococcal enterotoxin C from 72 hours (panel b).  Cells were stained 
for CD4 and CD25. 
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Figure 5.10.  Proportions of each cell population following incubation of bovine PBMCs in the 
presence or absence of 10μg/ml SEC for 72 hours.  Bars represent median values.  Panel (a): 
CD4+ cells, (b): CD8+ cells, (c) all CD4+ CD25+ cells and (d) CD8+ ACT2+ cells.   
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5.2.2   Effect of a Staphylococcus aureus strain transformed for staphylococcal enterotoxin C 
on bovine peripheral blood mononuclear cells 
To determine the effect of a S. aureus strain transformed for SEC on bovine PBMCs, we 
transformed the S. aureus RN4220 strain with the sec gene.  The gene for sec was amplified by 
PCR.  Primers were designed so that the promoter for sec was incorporated in the PCR product.  
The product was ligated into the pAW11 vector and was aligned in the opposite orientation to the 
promoter contained within the vector.  The ligation product was used to transform E. coli JM109 
cells and purified plasmid was obtained.  This was used to transform S. aureus RN4220 cells.  
The presence of the sec gene in the RN4220 cells was confirmed by PCR.  The pAW11 vector 
alone was used to transform S. aureus RN4220 and the resultant strain was used as a control.  
Secretion of SEC into cell culture supernatants was confirmed by western blot.  An attempt was 
made to make the western blot semi-quantitative using known dilutions of SEC to create a 
standard curve.  Unfortunately, the amount of SEC secreted into cell culture supernatants was 
insufficient to be compared with the standards by densitometry. 
 
The transformed strain (RN4220-SEC) was incubated with PBMCs for 24, 48 and 72 hours.  
Secretion of IFN-γ, IL-10 and TNF-α were significantly increased by S. aureus RN4220 however 
transformation with the sec gene did not affect cytokine concentrations (Figures 5.11, 5.12 and 
5.13).  Transcription of IL-4 mRNA was decreased by S. aureus RN4220 although the decrease 
appeared to occur 24 hours sooner when the strain was transformed for the sec gene (Figure 
5.14).  These data suggest that transformation of RN4220 with the sec gene causes a transient 
decrease in anti-inflammatory cytokine release. 
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Figure 5.11.  Effect of S. aureus RN4220 transformed with the pAW11 vector containing the sec 
gene on IFN-γ secretion by bovine PBMCs at 24, 48 and 72 hours of incubation compared with 
RN4220 transformed with vector alone.  Bars represent median values.  All isolates significantly 
increased IFN-γ secretion compared with media.  Transformation with the sec gene did not have a 
significant effect. 
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Figure 5.12.  Effect of S. aureus RN4220 transformed with the pAW11 vector containing the sec 
gene on IL-10 secretion by bovine PBMCs at 24, 48 and 72 hours of incubation compared with 
RN4220 transformed with vector alone.  Bars represent median values.  All isolates significantly 
increased IL-10 secretion compared with media.  Transformation with the sec gene did not have a 
significant effect. 
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Figure 5.13.  Effect of S. aureus RN4220 transformed with the pAW11 vector containing the sec 
gene on TNF-α secretion by bovine PBMCs at 24, 48 and 72 hours of incubation compared with 
RN4220 transformed with vector alone.  Bars represent median values.  All isolates significantly 
increased TNF-α secretion compared with media.  Transformation with the sec gene did not have a 
significant effect. 
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Figure 5.14.  Effect of S. aureus RN4220 transformed with the pAW11 vector containing the sec 
gene on IL-4 gene expression by bovine PBMCs at 24, 48 and 72 hours of incubation compared 
with RN4220 transformed with vector alone.  Bars represent median values.  Expression of IL-4 
mRNA was significantly decreased compared with media at 48 and 72 hours for RN4220 
transformed with sec and at 72 hours for RN4220 transformed with vector alone. 
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5.3 Establishment of a model of ovine intramammary infection 
A reliable model of ovine IMI with S. aureus is required before the effects of S. aureus on ovine 
mammary cellular immune responses can be determined.  Nine ewes which, between then, 
possessed 14 uninfected mammary halves were challenged with S. aureus isolates SA8 and SA10 
as summarized in table 4.3.  Due to the limited number of ewes available, some ewes were 
challenged with a different S. aureus isolate in each mammary half.  Based on morphological 
characteristics of recovered colonies, S. aureus strains did not move between mammary halves.  If 
a ewe was challenged with more than one S. aureus isolate, the same challenge dose was used for 
each.  All experimental intramammary challenges resulted in IMI which persisted for the duration 
of the study (Figures 5.15 and 5.16).  Repeated measures ANOVA revealed that bacterial shedding 
did not vary significantly for either SA8 (P = 0.56) or SA10 (P = 0.33).  As the animals used were 
non-lactating, it was not consistently possible to collect sufficient mammary secretion to determine 
udder half SCCs on each day of the study.  However, similar SCCs were observed following 
challenge in udder halves infected with each challenge dose (Figures 5.17 and 5.18).  Transient 
episodes of clinical mastitis were observed in two animals during the study.  Rectal temperature 
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did not vary more than 0.4°C from the rectal temperature recorded on the day of challenge (Figure 
5.19) and no systemic clinical signs were observed.  Due to the fact that some ewes were 
challenged with a different isolate in each udder half, the effect of each isolate on clinical disease 
could not be assessed. 
 
Given that both isolates generated subclinical disease at all doses and no significant differences 
were noted between doses, the 50cfu dose was chosen as the challenge dose for studies of the 
effect of S. aureus on mammary cellular immune responses in vivo. 
 
Figure 5.15.  Bacterial shedding from mammary halves of ewes challenged with 10cfu (circles), 
50cfu (squares) or 200cfu (triangles) of S. aureus isolate SA8 on days 3, 5, 9, 12 and 15 following 
challenge.  Data are presented as median cfu/ml.  Error bars represent range.  Bacterial shedding 
did not vary significantly between groups (P = 0.56) or between day post-challenge (P = 0.12). 
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Figure 5.16.  Bacterial shedding from mammary halves of ewes challenged with 10cfu (circles), 
50cfu (squares) or 200cfu (triangles) of S. aureus isolate SA10 on days 3, 5, 9, 12 and 15 following 
challenge.  Data are represented as median cfu/ml.  Error bars represent range.  Bacterial shedding 
did not vary significantly between groups (P = 0.33).  A significant effect of day post-challenge 
was observed, independent of challenge dose (P = 0.04). 
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Figure 5.17.  Udder half somatic cell counts from ewes challenged with 10cfu (circles), 50cfu 
(squares) or 200cfu (triangles) of S. aureus isolate SA8 on days 3, 5, 9, 12 and 15 following 
challenge.  Data are represented as median cfu/ml.  Error bars represent range. 
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Figure 5.18.  Udder half somatic cell counts from ewes challenged with 10cfu (circles), 50cfu 
(squares) or 200cfu (triangles) of S. aureus isolate SA10 on days 3, 5, 9, 12 and 15 following 
challenge.  Data are represented as median cfu/ml.  Error bars represent range. 
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Figure 5.19.  Median changes in rectal temperature of ewes challenged with different doses of S. 
aureus.  Animals were challenged with either 10cfu (circles), 50cfu (squares) or 200cfu (triangles) 
S. aureus.  As some animals were challenged with more than one S. aureus isolate, comparisons 
between isolates could not be obtained. 
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5.4 Effects of Staphylococcus aureus isolates on ovine mammary immune responses in vivo 
5.4.1 Generation of Staphylococcus aureus intramammary infections 
Lactating ewes were challenged with either 50cfu of SA8 or 50cfu of SA10 in a single udder 
half.  The contralateral udder half was used as an uninfected control.  Details of animals and 
udder halves infected are presented in table 4.5.  All animals developed a S. aureus IMI in the 
challenge half which persisted for the duration of the study.  There was no recovery of S. aureus 
from any unchallenged udder half.  Bacterial shedding was significantly lower six days post-
challenge with SA8  (P = 0.04) (Figures 5.20 and 5.21).  Milk SCCs were determined on the 
day of challenge and all days following challenge.  During the acute phase of infection, milk 
SCC did not vary between isolate, infection status of the mammary quarter or timepoint (Figure 
5.22).  During the chronic phase of infection, the SA10 isolate significantly increased milk SCC 
compared with every other treatment.  Otherwise, milk SCC did not significantly vary between 
isolate, infection status of mammary quarter or timepoint (Figure 5.23).  Clinical mastitis, 
characterized by abnormal mammary secretion, was noted on one study day for two infected 
udder halves.  Otherwise, no clinical mastitis was observed.  The lack of a significant effect of S. 
aureus IMI on milk SCC may either indicate that these isolates do not significantly increase SCC 
or that insufficient animals were used to determine statistically significant differences.  However, 
given that S. aureus IMIs were established that persisted for the duration of the study, the 
infection model was successful and allows for the determination of the effects of S. aureus IMI 
on mammary immune responses. 
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Figure 5.20.  Bacterial shedding from ewes challenged with 50cfu S. aureus SA8 (open bars) or 
SA10 (closed bars) and euthanized 3 days following challenge.  Data are represented as median 
cfu/ml.  Error bars represent range.  Bacterial shedding did not vary significantly between groups 
(P = 0.25) or between day post-challenge (P = 0.21). 
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Figure 5.21.  Bacterial shedding from ewes challenged with 50cfu S. aureus SA8 (open bars) or 
SA10 (closed bars) and euthanized 15 days following challenge.  Data are represented as median 
cfu/ml.  Error bars represent range.  Bacterial shedding was significantly lower in animals 
challenged with S. aureus SA8 six days post-challenge (P = 0.04). 
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Figure 5.22.  Udder half somatic cell counts from ewes challenged with 50cfu S. aureus SA8 
(open bars) or SA10 (closed bars) and euthanized 3 days following challenge.  Data are 
represented as median cfu/ml.  Error bars represent range.  Milk SCC did not vary with treatment 
(P = 0.35) or days post-challenge (P = 0.25). 
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Figure 5.23.  Udder half somatic cell counts from ewes challenged with 50cfu S. aureus SA8 
(squares) or SA10 (triangles) and euthanized 15 days following challenge.  Challenged halves are 
represented with filled symbols, control halves are represented with open symbols.  Data are 
represented as median cfu/ml.  Error bars represent range.  Milk somatic cell counts from udder 
halves challenged with S. aureus SA10 were significantly higher than those from all other 
challenges at day 3 post-challenge (P < 0.01). 
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5.4.2 Effect of Staphylococcus aureus isolates on leukocyte populations in supramammary 
lymph nodes 
Leucocyte surface marker expression in the SMLNs was quantified by flow cytometry.  Cell 
surface marker expression in the teat ends, mammary parenchyma and the SMLNs was determined 
qualitatively using IHC.  At euthanasia, it was observed that the control lymph node in one animal 
challenged with SA10 contained large amounts of purulent material therefore this lymph node was 
not excluded analysis.  Unfortunately, the purulent material was not saved for culture. 
 
The number of CD4+ cells during the acute phase of infection was significantly higher for animals 
challenged with SA10 than those challenged with SA8 (P = 0.007).  This effect was independent of 
infection status of the udder half (P = 0.80).  When data were analysed with the values for control 
halves subtracted from those for infected halves, numbers of CD4, CD8, γδ and CD11c positive T 
cells did not vary significantly between S. aureus isolates (P > 0.14) or with duration of infection 
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(P > 0.31).  Furthermore, no differences were observed between challenged and unchallenged 
halves (P > 0.43).  Representative flow cytometry profiles are shown in figure 5.24.  Data for acute 
and chronic infection are summarized in figures 5.25 and 5.26, respectively. 
 
At the teat end, IHC revealed large numbers of CD8 positive cells but few CD4 or γδ positive cells 
(Figure 5.27).  No CD11c positive cells were visible at the teat end.  No changes were observed as 
a result of infection, isolate or study day.  Results in the mammary parenchyma were variable.  
Some sections revealed typical mammary parenchymal morphology whilst others revealed 
significant cellular infiltration into the mammary gland with concurrent disruption of normal 
morphology (Figure 5.28).  These changes appeared to be independent of infection status and may 
reflect the fact that animals were at the end of lactation and entering the dry period.  Generally, the 
numbers of CD4+ cells were moderate, the numbers of CD8+ cells were high and the numbers of 
γδ, CD11c and CD205 positive cells varied from low to moderate.  Cells tended to be diffusely 
distributed throughout the mammary parenchyma.  However, chronic infection with S. aureus SA8 
appeared to increase the number of CD4 and CD205 positive cells (Figure 5.29).  CD205 is a 
marker for dendritic cells in the SMLN.  In some udder halves, aggregates of lymphoid cells were 
observed (Figure 5.30).  This appeared to be occurring independent of infection status of the udder 
half.  The morphology of SMLNs was as expected with a cortex containing follicles consisting of 
B cells, paracortex containing large numbers of T and B cells with low numbers of γδ cells and 
medullary cords containing T and B cells and low numbers of γδ cells (Figure 5.31).  As expected 
given the flow cytometry results, no differences in numbers of cells stained for each cell surface 
marker were observed between any of the groups. 
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Figure 5.24.  Representative flow cytometry profiles of leukocytes from supramammary lymph 
nodes in animals euthanized three days following challenge with 50cfu S. aureus SA8.  Panel (a) 
represents CD4+ cells, panel (b) represents CD8+ cells, panel (c) represents γδ T cell receptor + 
cells and panel (d) represents CD11c+ cells. 
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Figure 5.25.  Number of cells staining for CD4 (panel a), CD8 (panel b), γδ T cell receptor (panel 
c) and CD11c (panel d) leukocyte surface markers from the SMLNs of animals euthanized three 
days following challenge with 50cfu S. aureus SA8 (circles) or SA10 (triangles).  Challenged 
halves are represented with filled symbols, control halves are represented with open symbols.  The 
number of CD4 positive cells was significantly higher for animals challenged with SA10, 
regardless of infection status of the udder half (P = 0.007). 
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Figure 5.26.  Number of cells staining for CD4 (panel a), CD8 (panel b), γδ T cell receptor (panel 
c) and CD11c (panel d) leucocyte surface markers from the SMLNs of animals euthanized 15 days 
following challenge with 50cfu S. aureus SA8 (circles) or SA10 (triangles).  Challenged halves are 
represented with filled symbols, control halves are represented with open symbols.  Numbers of 
cells did not vary significantly between S. aureus isolates (P > 0.14) or with duration of infection 
(P > 0.31).  No differences were observed between challenged and unchallenged halves (P > 0.43). 
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Figure 5.27.  Sequential sections through the teat end of a ewe challenged with S. aureus isolate 
SA10.  These sections are representative of all the teat ends from animals used in the study.  Cells 
stained were CD4 (panel a), CD8 (panel b) and γδ T cells (panel c).  Cells positive for cell surface 
markers stain dark brown.  Few CD4 and γδ positive T cells are observed.  Many CD8 positive T 
cells are observed in cellular nests, connective tissue and invading the keratinizing epithelium of 
the teat canal. 
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Figure 5.28.  Sections from the mammary parenchyma of two different ewes.  Panel (a) represents 
normal secretory tissue.  Panel (b) represents mammary tissue with large scale cellular infiltration. 
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Figure 5.29.  Sections from the mammary parenchyma of a ewe challenged with S. aureus isolate 
SA8.  Cells stained were CD4 (panels a and b) and CD205 (panels c and d).  Panels (a) and (c) 
represent the control udder half; panels (b) and (d) represent the infected udder half.  Cells positive 
for cell surface markers stain dark brown.  Increased numbers of CD4 and CD205 positive cells are 
observed with chronic infection. 
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Figure 5.30.  Sections from the mammary parenchyma of a ewe illustrating aggregates of 
lymphoid cells.  Cells stained were CD4 (panel a), CD8 (panel b), γδ (panel c) CD11c (panel d).  
The organization of lymphoid cells occurred independent of infection status of the udder half. 
(a) (b)
(d)(c)
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Figure 5.31.  Sections from the supramammary lymph node of a ewe illustrating cortical follicles, 
paracortex and medullary cords.  Cells stained were CD4 (panel a), CD8 (panel b) and γδ (panel c).  
No differences between groups were observed for cellular staining characteristics. 
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5.4.3 Effect of Staphylococcus aureus on cytokine expression 
Cytokine expression at the teat end, in the mammary parenchyma and in the SMLNs was 
quantified using qRT-PCR.  Expression of IFN-γ was not significantly different between infected 
and uninfected udder halves for animals challenged with SA8 (Figure 5.32).  Expression of IFN-
γ was significantly higher in the teat ends of animals challenged with SA10 during the acute 
phase of infection when compared with uninfected controls (P = 0.01) (Figure 5.33).  When 
isolates and duration of infection were compared, no significant differences were noted.  
However, SA10 caused approximately five fold higher expression of IFN-γ at the teat end than 
SA8 which was independent of duration of infection but the difference was not statistically 
significant (P = 0.09). 
 
Figure 5.32.  Effect of S. aureus SA8 on IFN-γ expression at different sites during acute (3 days 
following challenge) and chronic (15 days following challenge) infection.  Data are expressed as 
relative expression normalized to the control udder half.  A relative expression value of 1 indicates 
no difference between challenged and control udder halves.  Expression of IFN-γ was not 
significantly different between infected and uninfected udder halves. 
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Figure 5.33.  Effect of S. aureus SA10 on IFN-γ expression at different sites during acute and 
chronic infection.  Data are expressed as relative expression normalized to the control udder half.  
A relative expression value of 1 indicates no difference between challenged and control udder 
halves.  Expression of IFN-γ was significantly higher at infected teat ends when compared with 
control teat ends during the acute phase of infection (P = 0.01). 
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Expression of IL-4 was not significantly different between infected and uninfected udder halves 
for animals challenged with SA8 or SA10 (Figures 5.34 and 5.35, respectively).  When isolates 
and duration of infection were compared, no significant differences were noted.  Expression of 
IL-10 was significantly lower in the SMLNs of animals challenged with SA8 during the acute 
phase of infection compared with uninfected controls (P = 0.04) (Figure 5.36).  Expression of IL-
10 was not significantly different between infected and uninfected udder halves for animals 
infected with SA10 (Figure 5.37).  When isolates and duration of infection were compared, 
expression of IL-10 was significantly higher in the teat ends of animals chronically infected with 
SA8 when compared with animals acutely infected with SA8.  Expression of IL-10 was also 
higher in the mammary parenchyma of animals challenged with SA10 compared with those 
challenged with SA8 (P = 0.09). 
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Figure 5.34.  Effect of S. aureus SA8 on IL-4 expression at different sites during acute and 
chronic infection.  Data are expressed as relative expression normalized to the control udder half.  
A relative expression value of 1 indicates no difference between challenged and control udder 
halves.  Expression of IL-4 was not significantly different between infected and uninfected udder 
halves. 
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Figure 5.35.  Effect of S. aureus SA10 on IL-4 expression at different sites during acute and 
chronic infection.  Data are expressed as relative expression normalized to the control udder half.  
A relative expression value of 1 indicates no difference between challenged and control udder 
halves.  Expression of IL-4 was not significantly different between infected and uninfected udder 
halves. 
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Figure 5.36.  Effect of S. aureus SA8 on IL-10 expression at different sites during acute and 
chronic infection.  Data are expressed as relative expression normalized to the control udder half.  
A relative expression value of 1 indicates no difference between challenged and control udder 
halves.  Expression of IL-10 was significantly lower in the SMLNs from infected udder halves 
when compared with uninfected controls.  Expression of IL-10 was significantly higher in 
chronically infected teat ends than acutely infected teat ends. 
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Figure 5.37.  Effect of S. aureus SA10 on IL-10 expression at different sites during acute and 
chronic infection.  Data are expressed as relative expression normalized to the control udder half.  
A relative expression value of 1 indicates no difference between challenged and control udder 
halves.  Expression of IL-10 was higher in the mammary parenchyma of animals challenged with 
SA10 than those challenged with SA8 (P = 0.09). 
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The source of cytokine expression in SMLNs was determined by flow cytometry using cells 
stained for cell surface markers and cytokines.  Numbers of CD4 positive cells expressing IL-10 
were significantly lower in the SMLNs of animals acutely infected with SA10 compared with 
uninfected controls and significantly higher in the SMLNs of acutely infected animals than 
chronically infected animals (P = 0.04) (Figure 5.38).  When baseline numbers of cells in control 
udder halves were subtracted, numbers of CD11c positive cells expressing IL-4 were significantly 
higher in the SMLNs of animals infected with SA8 than those infected with SA10 and in the 
acute phase of SA8 infection when compared with the chronic phase (Figure 5.39).  As noted 
above, expression of IL-10 was significantly lower in the SMLNs of animals challenged with 
SA8 during the acute phase of infection compared with uninfected controls.  However, no major 
differences in the number of CD4, γδ or CD11c positive cells expressing IL-10 were observed 
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(Figure 5.40).  Unfortunately, due to an experimental error in staining for flow cytometry, CD8 
positive cells expressing IL-10 were not assayed.  It remains a possibility that the decrease in IL-
10 observed during the acute phase of infection may be attributable to this cell population. 
 
 
Figure 5.38.  Numbers of CD4 positive cells expressing IL-10 from the SMLNs of animals 
infected with SA10.  Numbers of CD4 positive cells expressing IL-10 were significantly lower in 
animals acutely infected with SA10 compared with uninfected controls and significantly higher 
in acutely infected animals than chronically infected animals (P = 0.04). 
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Figure 5.39.  Numbers of CD11c positive cells expressing IL-4 from the SMLNs of animals 
infected with SA8 and SA10 at acute (panel a) and chronic (panel b) stages of infection.  When 
baseline numbers of cells in control udder halves were subtracted, numbers of CD11c positive 
cells expressing IL-4 were significantly higher in animals infected with SA8 than those infected 
with SA10 and in the acute phase of SA8 infection when compared with the chronic phase. 
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Figure 5.40.  Numbers of cells expressing IL-10 from the SMLNs of animals infected with SA8 at 
the acute stage of infection.  Cells assayed were CD4 (panel a), CD8 (panel b) and γδ positive 
(panel c).  No significant differences were observed. 
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6.  DISCUSSION 
 
The first objective of this study was to screen bovine mammary S. aureus isolates and determine 
whether they altered cytokine secretion by bovine PBMCs in vitro.  Three isolates had large 
effects on cytokine expression in vitro.  However, the remaining six isolates had similar 
responses.  This suggests that the majority of S. aureus isolates may have similar effects on 
cellular immune responses.  The general effect of these isolates was a moderate increase in IFN-γ 
and TNF-α secretion, a negligible increase in IL-10 secretion and no change in IL-4 expression 
when compared with media alone.  Of the three remaining isolates, two caused large increases in 
IFN-γ, TNF-α and IL-10 secretion and the third caused large increases in IFN-γ and TNF-α 
secretion alongside an increase in IL-4 expression. 
 
Previous studies have reported contradictory results regarding IFN-γ upregulation as a result of 
S. aureus IMI [4-6, 213-215].  These studies used a variety of difference S. aureus isolates and 
show that different isolates induce different increases in IFN-γ secretion.  The isolates 
(Newbould 305, strain DV137, uncharacterized wild type isolates) used were different to those 
used in our study.  Strain differences may explain differences that are observed between studies.   
 
Previous work has reported increases in IL-10 due to S. aureus IMI although the increases have 
been reported to be of a low magnitude [4, 5].  These data show that some S. aureus isolates 
increase IL-10 concentrations to a large degree whilst others cause minimal increases in IL-10 
concentrations, suggesting that strain dependence is important.  The minimal increases in IL-10 
appear to be as a result of secretion from CD8 and γδ positive T cells.  The increased IL-10 
secretion as a result of the SA8 isolate appears to be as a result of CD4 positive T cells.  These 
data seem to be consistent with those of Seo and coworkers [8] who showed increased CD4+ IL-
10 secreting cells in vitro when PBMCs were exposed to SEC.  Given that SA8 possesses the sec 
gene, this may be a reason for the observed results with SA8.  It appears that the low-virulence 
RN4220 strain causes increased secretion of IL-10 compared to many wild type strains.  The 
RN4220 strain is a laboratory strain that appears to lack enterotoxin genes [273], has minimal 
haemolysin production [274] and low activity of the virulence regulator agr as a result of a 
frameshift mutation at the 3’ end of agrA [275].  Several wild type strains may produce virulence 
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factors under the control of agr that result in decreased IL-10 production by CD8+ and γδ T 
cells. 
 
The role of IL-4 in S. aureus IMI has not been a major topic of previous studies.  It has been 
reported that IL-4 mRNA is not present in somatic cells from the milk of cows with S. aureus 
IMI [6].  The fact that IL-4 mRNA was present in the PBMCs of the current study reflects the 
different cell types assayed.  Studies in vivo will provide a far better comparison of whether IL-4 
mRNA can be isolated from the mammary gland. 
 
The moderate changes in cytokine expression observed due to the majority of S. aureus isolates 
is consistent with previous work which reports that S. aureus causes mild and transient increases 
in cytokine levels in milk [4, 213] when compared with those observed as a result of E. coli IMI.  
It has also been hypothesized that the reason for S. aureus IMI being a chronic disease is that 
pro-inflammatory cytokine levels do not rise sufficiently rapidly or to sufficiently high levels to 
clear infection.  However, certain isolates resulted in large IFN-γ and TNF-α responses which 
occurred rapidly yet the isolates were recovered from chronic S. aureus IMI.  It must be 
remembered that these isolates were recovered from individual animals therefore the behaviour 
of an isolate in an individual may not reflect its behaviour in an entire population.  Furthermore, 
other explanations may exist for the chronic nature of S. aureus IMI including the decreased 
concentration and function of immune effectors in the mammary gland compared with blood and 
the ability of S. aureus to prevent phagocytosis and killing by neutrophils allowing its 
localization within microabscesses and its shielding from host responses. 
 
During the in vitro studies, the most dramatic responses appeared to be associated with isolates 
possessing the sec gene.  However, strains that possess the sec gene had varying effects.  For 
example, the SA8 isolate caused increases in IFN-γ, IL-10 and IL-4.  The SA23 isolate caused 
increases in IFN-γ, IL-10, TNF-α and IL-4.  This suggests that these isolates seem to induce non-
specific stimulation of immune responses.  The SA10 isolate induced increases in IFN-γ, TNF-α 
and IL-4 but not IL-10.  This suggests that this isolate induces a balanced TH1 and TH2 response.  
Given that different isolates containing the sec gene have varying effects, experiments were 
carried out to characterize the role of sec alone and were detailed in section 5.2.  
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To characterize the role of sec, the first experiment investigated the effect of purified SEC 
protein on cytokine secretion and cell surface marker expression by PBMCs in vitro.  An 
increase in IL-10 secretion was observed from PBMCs of naive cattle exposed to SEC.  This 
evidence suggests that SEC promotes an anti-inflammatory response.  This is consistent with the 
results observed by Ferens and co-workers [259].  However, no change in the proportion of cells 
expressing specific leukocyte lineage markers (CD4, CD8, CD25, ACT2) was observed.  This is 
in contrast to an increase in CD4+ CD25+ cells following exposure to SEC reported by Seo and 
co-workers [8].  Experimental conditions in the current study differed to those in the previous 
study [8] in which PBMCs were stimulated with 5ng/ml SEC for 10 days.  Exposure of PBMCs 
to SEC for 10 days appeared to promote differential levels of proliferation of different cell 
populations.  Exposure to low doses of SEC protein for long periods may be necessary to induce 
CD4+ CD25+ cells.  The fact that the proportion of CD8+ or CD8+ ACT2+ cells did not change 
following exposure to SEC appears to be inconsistent with previous in vitro work using PBMCs 
[8, 257].  The previous studies used lower concentrations of SEC (0.1μg/ml and 5ng/ml 
respectively) than the current study therefore low SEC concentrations may also be needed to 
induce these cell populations.   
 
A fundamental problem with using purified SEC protein to assess the responses of PBMCs to 
SEC is that the physiological relevance of in vitro doses is unknown.  This is especially relevant 
since in vivo evidence suggests that the quantities of SEC protein secreted by S. aureus do not 
result in the generation of CD8+ ACT2+ cells [260].  A better approach is to use a S. aureus 
strain transformed for the sec gene that secretes SEC and compare it to an isogenic S. aureus 
strain that was not transformed for the sec gene therefore does not secrete SEC.  This approach 
was used in section 5.2.2.  Furthermore, only four animals were used as PBMC donors in section 
5.2.1 and they were beef animals with low antibody titres against S. aureus and SEC and the 
results obtained were probably more reflective of innate responses rather than adaptive immune 
responses to SEC.  The studies described in section 5.2.2 used eight dairy animals with recall 
immune responses to S. aureus allowing for better characterization of adaptive immune 
responses.  Finally, the effects of sec on IL-4 and TNF-α were also assayed as the limited 
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cytokine repertoire analysed using SEC protein prevented analysis of anti-inflammatory 
responses.  This provides a better model for evaluating the effect of SEC on cellular immunity.  
 
 
The only difference observed between the RN4220 strain and the RN4220 strain transformed for 
sec was a decrease in IL-4 expression which occurred earlier in the transformed strain.  This 
decrease in IL-4 mRNA appears to be contradictory to previous research which reported 
sustained increases in IL-4 production following exposure of PBMCs to SEC protein [259].  
However, given that the RN4220 isolate also decreased IL-4 mRNA expression therefore the 
effect observed may be a mild effect observed over time rather than a major difference between 
the isolates. 
 
Use of a S. aureus isolate transformed for sec should provide a more physiologically relevant 
model for the study of SEC in S. aureus pathogenesis.  The only previous study using a 
transformed S. aureus strain was an in vivo study which also showed no effect of the sec gene on 
the nature of mammary immune responses when compared to an isogenic S. aureus strain which 
did not contain the gene [260].  Several potential reasons exist for the differences observed 
between studies which use purified SEC protein and those that use a transformed S. aureus 
strain.  Firstly, the transformed strains appear to secrete very low concentrations of SEC.  Whilst 
these concentrations may be too low to cause any changes in milk or cell cultures, local SEC 
concentrations in vivo may rise to sufficiently high levels that biologic effects may occur at 
discrete sites in the mammary gland.  This may lead to the generation of small foci in which S. 
aureus may be evading immune responses.   
 
Staphylococcal enterotoxin C may operate in conjunction with other virulence factors.  The 
RN4220 isolate is a laboratory isolate with minimal virulence and it may lack the expression of 
virulence factors that enhance the effects of SEC.  To test this hypothesis, attempts were made to 
create a sec mutant strain of S. aureus from a wild type S. aureus isolate.  A construct of sec was 
generated in which a 100bp deletion was made and replaced with the kanamycin resistance gene 
aphA-3.  This was used to successfully transform E. coli DH5α and S. aureus RN4220.  
Transformation of a wild type S. aureus isolate possessing the sec gene was unsuccessful and 
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was probably as a result of the restriction modification system in wild type isolates.  Therefore, 
this hypothesis was not tested. 
 
Given that the prevalence of sec in S. aureus isolates from bovine mastitis appears to be low 
[86], sec may not be an important virulence factor in the pathogenesis of S. aureus IMI.  This 
may also explain the apparent lack of an effect of SEC on mammary immune responses in vivo 
and in studies which use a S. aureus isolate transformed for sec. 
 
Weaknesses of the experiments discussed so far include the fact that isolates were studied in 
vitro and that the role of DCs was not characterized.  This work was carried out in vitro so that a 
large number of S. aureus isolates could be characterized whilst minimizing the use of animals.  
Furthermore, the use of PBMCs from the same group of cattle removes variation among 
individual animals when comparing responses.  However, results in vitro are not always reflected 
in vivo. As transformation of S. aureus for the sec gene did not have significant effects in vitro, 
wild type isolates were chosen for the in vivo studies.  Given that the isolates that caused the 
most dramatic cytokine responses either caused a non-specific response or a balanced response, 
we chose an isolate representative of each of these responses to use in vivo.  These isolates were 
SA8 and SA10.  As has been previously discussed, DCs are central to the induction of different 
cellular immune responses therefore DC responses were characterized in the in vivo studies.  
Dendritic cell responses were characterized by staining DCs using cell surface markers followed 
by intracellular cytokine staining.   
 
To characterize responses in vivo, a model of S. aureus IMI was required.  An ideal model of 
IMI would be to use lactating dairy cattle.  However, due to the numbers of animals and 
associated handling facilities required, the costs associated with such a trial would have been 
prohibitive.  Some previous studies have used mice as experimental models of bovine mastitis.  
However, it has previously been reported that the roles of cytokines as determined in murine 
models cannot be extrapolated to bovine responses [168].  Sheep have also been previously used 
as experimental models for bovine S. aureus IMI due to their similarity in immune responses to 
cattle [276-278].  The increased ease of handling and decreased cost of sheep compared with 
cattle make them a practical alternative to dairy cattle in studies of S. aureus IMI.  However, it 
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must always be remembered that this is a model of IMI and results obtained may not always 
reflect the situation in the bovine.  Specifically, the metabolic requirements of a lactating dairy 
cow are likely to far exceed those of a lactating ewe. 
 
The original intention in developing the model of ovine S. aureus IMI was to challenge three 
udder halves with each of the three challenge doses of each S. aureus (10, 50 and 200 cfu).  This 
would have required 18 uninfected udder halves.  Based on the screening work performed, only 
14 uninfected udder halves were available from the available population of ewes therefore the 10 
cfu doses were administered to three udder halves whilst the 50 and 200 cfu doses were 
administered to two udder halves.  All challenge doses of both S. aureus isolates induced an IMI.  
Even though no significant differences in bacterial shedding were noted between challenge 
doses, the 10 cfu dose of the SA8 isolate resulted in generally lower bacterial shedding than the 
other doses.  No differences in SCC were noted between challenge doses.  Given that only 
transient episodes of clinical mastitis were noted in two animals and rectal temperature varied by 
no more than 0.4°C during the study, subclinical mastitis was induced by all challenge doses.  As 
a result of these observations, the 50 cfu dose was chosen as the challenge dose for studies of 
mammary cellular responses in vivo. 
When animals were challenged to determine mammary cellular responses, challenge with 50 cfu 
of either isolate generated a subclinical S. aureus IMI which persisted for the duration of the 
study, demonstrating a persistent IMI was established.   
 
Following arrival of an antigen at a regional lymph node, CD4+ T cells specific for that antigen are 
trapped in the lymph node [279].  Expansion and differentiation of T cell populations follows such 
that antigen specific T cells capable of directing the immune response are present.  Therefore, one 
might have expected an increase in both CD4+ and CD8+ T cell populations in the SMLNs 
following S. aureus IMI.   Animals challenged with SA10 had significantly higher numbers of 
CD4+ cells in the SMLNs three days following infection.  As this change was observed in both 
infected and uninfected udder halves, it may reflect a systemic effect of SA10 infection on CD4 
positive cell numbers.  Fifteen days following infection, the SA8 isolate appeared to increase the 
numbers of CD4, CD8 and γδ positive T cells in the lymph nodes draining infected udder halves 
although the changes were not statistically significant.  It would be interesting to report this 
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experiment with more animals to observe if these changes were repeatable.  If so, changes may 
reflect an expected induction of adaptive cellular immune responses at the local lymph node.   A 
similar increase in CD4 positive cells was observed fifteen days following SA10 infection.  This 
may also reflect induction of adaptive responses although the lack of CD8 cell recruitment may 
indicate that cytotoxic T cells are not being generated.  A previous study [212] reported no 
significant alterations in SMLN leukocyte populations following S. aureus IMI.  However, this 
study analysed leukocyte populations using immunohistochemistry and did not quantify changes in 
cell populations.  It is to be expected that the current study is of increased sensitivity due to the use 
of flow cytometry for accurate quantification of leukocyte populations.  
 
Immunohistochemical staining revealed no major effects of S. aureus IMI on local leukocyte 
populations.  However, it must be remembered that IHC is a very subjective method of analysis 
and is better suited to evaluation of tissue morphology rather than absolute numbers of cells in 
tissue.  The observed increase in CD4 and CD205 positive cells fifteen days following SA8 
infection may reflect a local immune response.  Leitner and co-workers [212] reported an increase 
in the numbers of CD8 positive cells in mammary parenchyma as a result of S. aureus IMI greater 
than three months in duration.  It has also been reported that the numbers of CD4 and CD8 positive 
cells in milk increase as a result of S. aureus IMI greater than two months in duration [6].  We did 
not observe an increase in CD8 positive cells.  The results presented here are more consistent with 
recruitment of CD4 positive T helper cells and myeloid cells differentiating into DCs in the 
mammary gland of animals chronically infected with S. aureus.  Our studies may not have 
analysed infections of sufficient duration to observe recruitment of immune effectors into the 
mammary gland although we may be observing the induction of cellular responses in infected 
tissue. 
  
The development of lymphoid aggregates in the mammary gland was an interesting and 
unexpected observation.  Organization appeared to occur independent of infection status of the 
mammary half although only a small proportion of the gland is observed using IHC.  A potential 
explanation for this observation is that the animals in the study all had recall immune responses to 
S. aureus (Table 4.4).  Even though animals were not infected with S. aureus at the beginning of 
the study, this does not rule out previous S. aureus IMI or IMI with other mastitis pathogens that 
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resulted in chronic inflammation in mammary parenchyma and establishment of these lymphoid 
aggregates. 
 
Whilst observation of changes in cell populations is useful in the evaluation of mammary cellular 
immune responses, it does not give any information regarding cell function and the nature of the 
immune response generated.  Evaluation of changes in cytokine levels in each of these locations 
and investigation of the cell types that secrete each cytokine enables us to determine this 
information. 
 
Our data revealed that the SA8 isolate was associated with decreased IL-10 expression in the 
SMLNs during acute infection.  No differences were noted in CD4, γδ or CD11c positive cells 
expressing IL-10 as a result of SA8 infection.  As no data are available regarding CD8 positive 
cells expressing IL-10, the contribution of this cell type to SA10 levels cannot be determined.  
Infection with SA8 did result in an increase in CD11c+ IL-4 secreting cells in the SMLN.  The 
SA10 isolate caused increased IFN-γ expression in the teat ends during acute and chronic 
infection.  The SA10 isolate also decreased CD4+ IL-10 expressing cells in SMLNs during acute 
infection. 
 
Previous studies have reported contradictory results regarding cytokine expression in S. aureus 
IMI.  For example, studies have reported that IFN-γ levels in milk may increase [4-6] or remain 
unchanged following S. aureus IMI [213].  Our data may provide an explanation for these 
differing results in that IFN-γ increased in the teat ends of animals challenged with SA10 but not 
in those challenged with SA8.  However, we observed no changes in IL-10 expression in the 
mammary parenchyma following infection with either isolate.  It is difficult to draw comparisons 
between cytokine levels at different locations and those in milk but one might expect changes in 
mammary parenchyma to most closely reflect those in milk.  The only previous study of IL-4 
levels in milk reported that no IL-4 mRNA was present in milk somatic cells.  The data reported 
in the current study indicates that IL-4 mRNA was isolated from different sites in the mammary 
gland.  The lack of IL-4 mRNA in milk somatic cells may reflect the fact that the majority of 
milk somatic cells during S. aureus IMI are neutrophils therefore are unlikely to express IL-4.  
No differences in IL-4 expression were observed in any of the sites assayed in the current study.  
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However, in the SMLNs of animals infected with SA8 we observed an increase in CD11c+ cells 
expressing IL-4.  Even though no changes in expression were observed on qRT-PCR, we might 
be observing an early shift towards an IL-4 response.  If the animals were euthanized at a later 
date, more evidence for an IL-4 response may have been obtained.  Previous studies all report an 
increase in milk IL-10 following S. aureus IMI during the acute (48 hours following challenge) 
[4] or chronic [6] (greater than three months following challenge) phases of infection.  A 
decrease in IL-10 was observed during the acute phase of infection with SA8 followed by an 
increase in IL-10 during the chronic phase in the current study.  This may reflect differences in 
the S. aureus isolates used since Newbould 305 was used to observe responses 48 hours 
following challenge and multiple wild type isolates were used to observe responses greater than 
three months following challenge. 
 
A major limitation of the in vivo work is the low numbers of animals in each group.  This was due 
to the very limited availability of lactating ewes that were negative for S. aureus on three 
consecutive milk cultures before the study.  The limited number of animals increases the likelihood 
of type II statistical error in which the hypothesis that no difference exists between the groups is 
inappropriately retained.  Repeating this work with increased numbers of animals would confirm 
the results that we have observed and may increase the chance of observing significant differences. 
 
During the in vivo studies, qRT-PCR was used to determine cytokine expression in tissue.  This 
technique was chosen due to its high sensitivity in detecting mRNA in tissue.  A recent study 
characterized the kinetics of ovine IFN-γ and IL-10 mRNA and protein in vitro [280].  Animals 
used as blood donors had been previously immunized with OVA.  When PBMCs collected from 
these animals were restimulated in vitro with OVA, IFN-γ mRNA levels increased for the first 48 
hours after restimulation and then decreased slightly until 96 hours.  When IFN-γ protein levels 
were assayed, protein levels remained low over the first 48 hours but then increased up until 96 
hours.  Following restimulation, IL-10 levels peaked at 6 hours, then decreased until 24 hours and 
remained at a plateau.  Increased IL-10 protein levels began at 6 hours and continued to increase 
until 96 hours.  These data suggest that changes in mRNA levels precede those of protein.  While 
these data appear to support the use of qRT-PCR to determine tissue cytokine expression, it must 
be remembered that cytokine gene expression and protein production occur at different times 
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therefore results here may not have been reflective of cytokine protein assays performed at the 
same timepoints.  Also, qRT-PCR does not take cell recruitment into account.  Specifically, if 
increased numbers of cells are secreting cytokine, cytokine protein levels will increase even though 
gene expression, as assayed by qRT-PCR, will remain unchanged. 
 
In summary, the two S. aureus isolates generated significantly different responses.  For both 
isolates, we observed an initial acute inflammatory response at the teat end which was 
characterized by an increase in IFN-γ levels.  This increase persisted to day 15 following SA10 
infection.  Increases in IFN-γ 15 days following SA10 infection occurred in the mammary 
parenchyma and SMLNs, suggesting a pro-inflammatory response, although the range of data 
recorded is large and not statistically significant.  No major changes in IL-4 levels occurred as a 
result of IMI.  However, CD11c+ IL-4 expressing cells increased significantly as a result of SA8 
IMI which may reflect the early stages of an IL-4 response.  A decrease in IL-10 expression was 
observed at the teat ends and SMLNs during the acute phase of infection.  Teat end IL-10 
expression increased during the chronic phase.  These changes may reflect an initial decrease in 
IL-10 levels as a result of acute inflammatory responses followed by a regulatory response in the 
teat end.  This would be reflective of the changes observed as a result of SA8 in vitro. 
 
Differences also exist between cytokine responses observed in vitro and in vivo.  These 
differences may result from differences between the experimental models.  The first difference is 
that sheep and cattle were used and care should be taken in directly comparing immune 
responses between species. 
 
The major difference between in vitro and in vivo models is the more complete anatomic 
localization of T cell recruitment in vivo.  This is especially relevant when antigen presentation is 
considered.  When PBMCs are isolated, the resulting cell mixture consists of a majority of 
lymphocytes alongside monocytes and monocyte-related cells such as DCs [281].  Dendritic 
cells in blood tend to be in an immature state with low levels of MHC proteins and costimulatory 
molecules and are thus far less able to induce T cell responses than are those in tissue [281].  
Immature dendritic cells in tissue possess this immature phenotype and have high phagocytic 
capacity.  Acquisition of antigen and migration of DCs to the draining lymph node is associated 
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with DC maturation and antigen presentation [282].  Given that migration to the regions lymph 
node cannot occur in vitro, antigen presentation is likely to be as a result of monocytes and 
immature DCs.  Antigen presentation will not be anatomically linked therefore will be less 
efficient.  Therefore, the majority of the antigen-specific response in vitro will probably by 
memory T cells in the blood that have not yet trafficked to a lymph node at a site of antigenic 
stimulation.  The animals used for in vitro studies had prior exposure to S. aureus and memory T 
cells are thought to retain the cytokine secreting characteristics present in the initial immune 
response [283].  They appear to be more effective in generating T cell help than cells induced 
during primary immune responses [284].  This suggests that stimulation of PBMCs in this work 
will result in the secretion of the same cytokines as those that occurred when animals were 
initially exposed to S. aureus antigens.  However, the magnitude of the increases may be 
exaggerated.  Furthermore, the presence of teichoic acid in the staphylococcal cell wall may act 
as a stimulus for T cell proliferation, further exaggerating the magnitude of changes. 
 
When animals are challenged in vivo, antigen presentation can occur by DCs and the DCs 
themselves can influence T cell responses.  Memory T cells will also play a role in our model as 
the animals had prior exposure to S. aureus.  It is likely that the acute responses observed in vivo 
reflect innate immunity.  The innate responses are reflected in the increases in IFN-γ observed at 
the teat end in response to each S. aureus isolate.  As the immune responses move into the 
chronic phase, both DCs will play a role.  We studied the function of DCs in the SMLNs using 
flow cytometric staining for cytokines.  The only significant change noted was an increase in 
CD11c+ IL-4 expressing cells following SA8 IMI.  This increase may reflect stimulation of 
TLR2 by lipoteichoic acid on the S. aureus cell surface.  However, as has been discussed, there 
was no evidence of an overall IL-4 response. 
  
As the overall changes observed could not be explained by the results observed in SMLN DCs, it 
is likely that memory T cells played a major role.  This is the most likely explanation for the 
increase in IFN-γ observed during the chronic phase of SA10 IMI.  The initial exposure of these 
animals to S. aureus may have promoted the formation of DCs with a TH1 bias and generated a 
TH1 response.  This response recurred when the animals were challenged with S. aureus during 
the current study. 
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It is important to discuss how the changes that we have observed may be important in the 
pathogenesis of S. aureus IMI.  During the acute phase of IMI, we observed inflammatory 
responses at the teat end.  Results with the SA8 isolate suggest that it may induce an anti-
inflammatory response characterized by IL-4 and IL-10 in vivo although the responses to SA8 
were generally of a low level and not statistically significant.  This is similar to the in vitro 
changes observed in PBMC cultures following exposure to the majority of S. aureus isolates and 
may reflect an adaptation of S. aureus to prevent the generation of protective cellular immune 
responses and thus enhance bacterial survival in the mammary gland.  Results with the SA10 
isolate suggest that it may induce a pro-inflammatory response characterized by IFN-γ in vivo.  
This response is considered to be appropriate for a pathogen such as S. aureus which is able to 
become intracellular.  Although the available evidence suggests that SA10 is able to survive in 
the mammary gland, the evidence is limited to observations in the in vivo studies carried out in 
this study.  Studies with increased numbers of animals may reveal that SA10 is less likely to 
survive within the mammary gland than other S. aureus isolates.  It must also be remembered, 
however, that S. aureus possesses other virulence factors that may facilitate its survival in the 
mammary gland.  Also, as has been already discussed, immune responses in the mammary gland 
appear to be less effective than those in blood making the survival of S. aureus more likely. 
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7.  CONCLUSIONS 
 
The data presented show that different S. aureus isolates have different effects on mammary 
gland cellular immune responses.  However, the same isolates do not have identical effects in 
vitro and in vivo.  The differences between the in vitro and in vivo effects may be explained by 
differences between the models as a result of differences in antigen presentation, the role of 
memory T cells and the different species of animal used in each model.  In summary, SA8 
appears to induce pro-inflammatory and anti-inflammatory responses in vitro but appears to 
generate an anti-inflammatory response in vivo.  The SA8 isolate does increase IFN-γ at the teat 
end at the acute phase of infection.  This may be suggestive of a pro-inflammatory response at 
the teat end alone.  The SA10 isolate appeared to induce pro-inflammatory and anti-inflammatory 
responses in vitro but only generated a pro-inflammatory response in vivo. 
 
Staphylococcal enterotoxin C appears to cause a regulatory T cell response when purified protein 
used to stimulate PBMCs in vitro.  It did not have any effect when secreted by a transformed 
bacterial strain therefore no effect of SEC is apparent when it is present at physiologic conditions.  
Given that the strain transformed was a low virulence strain, SEC may work in conjunction with 
other virulence factors.  Generation of a sec mutant S. aureus strain would have tested this 
hypothesis but this strain could not be made.  Given that the two S. aureus isolates tested in vivo 
both possess the sec gene and that the prevalence of the sec gene is relatively low, it might be 
expected that sec has minimal effects on mammary gland immune responses. 
 
The results of this work suggest that different S. aureus isolates have distinct effects on mammary 
gland immune responses.  One of the isolates (SA8) appears to generate an anti-inflammatory 
response in vivo but both pro-inflammatory and anti-inflammatory responses in vitro.  A different 
isolate (SA10) appears to generate both pro-inflammatory and anti-inflammatory responses in vitro 
and in vivo.  Therefore, the original hypothesis for this work is valid for some S. aureus isolates but 
not others. 
 
The results of these studies illustrate the limitations of in vitro studies when determining immune 
responses to S. aureus as in vivo and in vitro studies reported different effects.  Also, the 
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limitations of investigating immune responses using a single isolate are illustrated.  Future studies 
should focus on investigating immune responses in vivo and should characterize responses to 
different strains.  This may have implications for future vaccine strategies in that strains selected to 
immunize against S. aureus should generate protective immunity and should be tested against 
infection with different S. aureus strains.  Future studies should also focus on the site of infection 
and not just assay markers of immune responses in milk. 
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